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     Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and 
their associated genes (cas) encode an adaptive, small-RNA-based immune 
system that protects prokaryotes from infectious phages and plasmids. CRISPR-
Cas systems can be classified into three types based on their cas gene content. 
My thesis work focused on two parts. First, I investigated the mechanism and 
function of RNA cleavage in type III CRISPR-Cas immunity. Secondly, I 
developed a tool to manipulate prokaryotic genomes and gene expression by 
using an engineered type II CRISPR-Cas system.  
     To date, all three types of CRISPR-Cas systems target DNA. Type III 
CRISPR-Cas immunity displays an elaborate targeting mechanism and 
distinguishes itself from type I and type II systems in at least two ways. My 
previous work in collaboration with other members of the lab helped to discover 
that the system cleaves both DNA and RNA molecules, and that active 
transcription across the target is necessary for targeting. Whereas DNA cleavage 
is required for phage DNA clearance and essential for immunity against infection, 
the function of RNA cleavage is unknown. It is well established that gene 
expression of many phages is temporally regulated. Using a type III-A CRISPR-
Cas system of Staphylococcus epidermidis as a model, I first identified a new 
CRISPR-associated RNase, Csm6. The transcriptional requirement for DNA 
cleavage created a challenge for host bacteria. When the target was located in a 
late-expressed phage gene, the phage infection cycle can proceed unchecked 
until the target was transcribed, resulting in a sharp increase of viral genomes in 
host cells. In this targeting condition, genetic inactivation of the type III-A RNases 
Csm3 and Csm6 led to the accumulation of the target phage mRNA and 
abrogated immunity. Csm6 was also required to provide defense in the presence 
of mutated phage targets, when DNA cleavage efficiency was reduced. My 
results showed that the degradation of phage transcripts by CRISPR-associated 
RNases ensures robust immunity in situations that lead to a slow clearance of 
the target DNA. 
     Recent work on the type II CRISPR-Cas adaptive immune systems has led to 
the discovery of Cas9, a dsDNA nuclease whose sequence specificity is 
programmed by small CRSPR RNAs (crRNAs). In collaboration with Dr. David 
Bikard, a former colleague, we found when reprogrammed to target the genomes 
of host bacteria, CRISPR can target and kill the cells. The lethal consequence 
upon targeting made CRISPR-Cas a novel tool for sequence-specific counter-
selection. When combined with editing templates, we demonstrated fast and 
efficient genome editing in Streptococcus pneumoniae, Escherichia coli (when 
used in combination with λ-Red recombination) and Staphylococcus aureus. 
Later, we inactivated the nuclease domains of Cas9, creating a catalytically dead 
Cas9 (dCas9) which retained DNA binding activity. We demonstrated that dCas9, 
when programmed with appropriate crRNAs, acted as a transcription repressor 
by preventing the binding of the RNA polymerase (RNAP) to promoter 
sequences or as a transcription terminator by blocking the elongating RNAP. In 
addition, a fusion between the ω subunit of the RNA polymerase and dCas9 
allowed for programmable transcription activation. The easy programmability and 
high specificity of crRNA-guided Cas9 and dCas9 greatly facilitates both genome 
editing and modulation of gene expression, and is likely to substantially advance 
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CHAPTER 1 INTRODUCTION 
1.1 Bacteriophages and their life cycles 
Figure 1-1 Bacteriophage T4 
(A) An electron micrograph of bacteriophage T4; adapted from (Miller et al. 2003). 
(B) A phage (in this case T4) is composed of a proteinous head and tail structure. 
The head encapsulates its DNA or RNA genome. The image is adapted from 
“https://en.wikipedia.org/wiki/Bacteriophage” with modifications.  
     Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and 
their associated genes (cas) encode an adaptive, small-RNA-based immune 
system that protects prokaryotes from infectious phages and plasmids. The 
immunity pathway is divided into three stages: adaptation, CRISPR RNA (crRNA) 
biogenesis and targeting. On the basis of cas gene conservation and operon 
organization, CRISPR-Cas can be divided into three major types. In addition to 
being an immune system, CRISPR-Cas has been repurposed as a versatile tool 
for genome editing. A recent review (Jiang and Marraffini 2015) written by my 
2 
advisor, Dr. Luciano Marraffini and me summarizes current understanding of 
CRISPR-Cas biology in prokaryotes and its many applications in biotechnology.  
Figure 1-2 Phages predate on bacteria 
A transmission electron micrograph of a thin section of Escherichia coli K-12 
infected with phage T4. Dark materials are phage DNA. Image courtesy of John 
Wertz.  
     Bacteriophages (Figure 1-1), or phages for short, are viruses that infect and 
replicate within bacteria (Figure 1-2). First discovered independently by Fredrick 
Twort and Felix d’Herelle in 1915 (Twort 1915) and 1917 (d'Herelle 1917), 
phages are probably the most abundant and genetically diverse entities known to 
exist in biology. It is estimated there are 1031 phages on Earth (Hatfull 2008), and 
they infect an estimated 1023 bacteria per second (Suttle 2007). Because their 
massive predation on bacteria that live in the ocean, soil as well as the human 
gut, phages play a tremendous role on global ecology (Wommack and Colwell 
2000) and human health (Reyes et al. 2012). Historically, studies conducted on 
phages between the years 1940 and 1970 laid much of the most fundamental 
groundwork for modern molecular genetics. For instance, experiments with 
3 
phage T4 uncovered the existence of mRNA, the nature of the genetic code and 
the function of ribosome (Karam 1994). In addition, basic research on phages 
has led to the development of many useful tools such as phagemids, phage-
plasmid hybrids that can be used as an efficient delivery method of nucleic acids 
into bacteria (Westwater et al. 2002). Phage display is another powerful 
technique for the study of protein-protein and protein-DNA interactions (Smith 
1985; Kehoe and Kay 2005). With this technique, large libraries of proteins can 
be screened and amplified through in vitro selection, a process widely used in 
drug discovery (Smith and Petrenko 1997). The infectious nature of phages is 
also harnessed as antibacterial agents (Nobrega et al. 2015), which offer a 
plausible solution to the rise of multi-drug resistant infectious bacteria caused by 
conventional antibiotic treatment.  
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Figure 1-3 Lytic and lysogenic life cycles of phages 
(A) In a lytic cycle, an infective phage immediately initiates reproduction and 
lyses host cells to release its progeny. (B) In a lysogenic cycle, a phage inserts 
its genome into the bacterial chromosome to become a prophage, which is 
replicated along with the bacterial DNA. (C) Under certain conditions such as 
DNA damage, the lysogenic cycle can convert to the lytic cycle as shown in (A). 
This figure is adapted from Microbiology, 7/e © 2008 John Wiley & Sons.  
     Generally, a phage is composed of a protein capsid that encapsulates a DNA 
or RNA genome (Figure 1-1B). In many cases, the capsid, also known as the 
head, has a tail structure attached to it. The tail structure is a hollow tube made 
of proteins that allows the phage to penetrate bacterial membrane and cell wall 
and inject its genetic material into the cell. Upon infection, phages typically 
sustain two distinct life cycles – lytic and lysogenic (Figure 1-3) (Herskowitz and 
5 
Hagen 1980). Lytic phages immediately enter a reproductive phase, in which 
their genetic material is replicated and packaged into a few hundred of progeny 
phage particles. The lytic cycle concludes with lysis of the host bacteria and 
release of phage progeny. By contrast, temperate phages can adopt either of the 
two life cycles, depending on their genetic circuits and environmental factors. If 
the lysogenic cycle is chosen, a single copy of the phage genome integrates into 
the bacterial chromosome to become a prophage, which is replicated together 
with the host chromosome. A switch to the lytic cycle can initiate under certain 
stress conditions such as DNA damage (Herskowitz and Hagen 1980). During 
this, the once-dormant prophage excises from the bacterial genome and follows 
the program similar to that of a lytic phage. The lysis-lysogeny decision has been 
a paradigm for gene regulatory network, and has been extensively characterized 
in the temperate phage λ (Oppenheim et al. 2005). 
     For many large double-stranded DNA phages such as T4 and λ, expression of 
phage genes is temporally regulated (Miller et al. 2003; Oppenheim et al. 2005). 
Immediately transcribed upon infection, most early genes encode enzymes 
involved in DNA replication and phage-encoded RNA polymerases that turn on 
late phage genes. These genes usually encode various phage parts such as the 
head and tail structures, packaging machinery and lytic enzymes that degrade 
bacterial cell walls. Temporal gene regulation is a “clever” way to ensure efficient 
utilization of host resources, and to control the timing of cell lysis so that an 
optimum number of phage progeny can be produced.  
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1.2 CRISPR-Cas is a small-RNA-based adaptive immune system in 
prokaryotes 
     Bacteria have evolved different ways to protect themselves against phage 
infections. Some of the best-known types of phage defense mechanisms are 
restriction-modification (Wilson 1991; Tock and Dryden 2005), abortive infection 
(Chopin et al. 2005) and CRISPR-Cas.  
     CRISPR-Cas systems encode an adaptive, small-RNA-based immune system 
that protects prokaryotes from infectious phages and plasmids (Deveau et al. 
2010; Horvath and Barrangou 2010; Terns and Terns 2011; Wiedenheft et al. 
2012; Barrangou and Marraffini 2014). A typical CRISPR-Cas locus in bacteria 
and archaea is composed of the CRISPR array and CRISPR-associated genes 
(cas) (Figure 1-4A).The CRISPR array is a cluster of short repetitive sequences 
(30-40 bp long) separated by equally short “spacer” sequences. Many spacer 
sequences match the genomes of phages and plasmids of bacteria and archaea 
(Bolotin et al. 2005; Mojica et al. 2005; Pourcel et al. 2005). This observation led 
to the hypothesis that CRISPR systems protect prokaryotes from infection by 
these genetic elements (Bolotin et al. 2005; Mojica et al. 2005; Pourcel et al. 
2005; Makarova et al. 2006). The bioinformatics predictions were first 
demonstrated by two experimental studies showing that CRISPR loci prevent 
viral (Barrangou et al. 2007) and plasmid (Marraffini and Sontheimer 2008) 
infection. 
     CRISPR-Cas immunity is divided into three stages (Figure 1-4). In the first 
stage, known as the adaptation phase, Cas proteins integrate short regions of 
7 
the invader’s genome into the CRISPR array as new spacers (Figure 1-4A). 
Reviews about this phenomenon are published elsewhere (Heler et al. 2014). In 
the second stage, the CRISPR array is transcribed and processed by Cas 
proteins to generate small CRISPR RNAs (crRNAs) that contain a full or partial 
spacer sequence (Figure 1-4B-D). During the third stage, or the targeting phase, 
processed crRNAs associate with Cas nucleases to guide the ribonucleoprotein 
complex to the target sequence (Figure 1-4B-D). Cleavage of the target 
sequence, also known as protospacer, results in both the destruction of the 
invader’s genome and immunity. On the basis of cas gene conservation and 
operon organization, CRISPR prokaryotic immune systems can be divided into 
three major types (Makarova et al. 2011), each of which presents variations of 
the general immunity mechanism described above (Figure 1-4B-D). 
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Figure 1-4  Three stages of CRISPR-Cas immunity 
(A) A typical CRISPR-Cas locus in bacteria and archaea is composed of a 
CRISPR array and CRISPR-associated genes (cas). In the first stage, known as 
the adaptation phase, Cas proteins acquire a short sequence of the genetic 
material of viral and plasmid invaders, known as a “spacer”, and integrate it into 
the first repeat of the CRISPR array, establishing a memory of infection. (B-D) In 
the second stage, known as the crRNA biogenesis phase, the CRISPR array is 
transcribed as a precursor crRNA (pre-crRNA), which is processed by Cas 
proteins into a short crRNA (mature crRNA). In the third stage, known as the 
targeting phase, the crRNA acts as a guide to specify the target of cleavage by 
Cas nucleases. Based on the cas gene content, there are three different types of 
CRISPR-Cas systems. They differ in the mechanisms of crRNA biogenesis and 
targeting, but also possibly in the mechanisms of adaptation as well. Closed and 
open arrowheads indicate RNA and DNA cleavage, respectively. Abbreviations: 
crRNA, CRISPR RNA; PAM, protospacer-adjacent motif; RNAP, RNA 
polymerase; tracrRNA, trans-encoded crRNA.  
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1.2.1 Type I CRISPR-Cas systems 
     Type I CRISPR-Cas systems encode proteins that form CRISPR-associated 
complex for antiviral defense (Cascade) and Cas3 (Figure 1-4B). The CRISPR 
array is transcribed as a long precursor crRNA that is processed at the repeat 
sequences to liberate short, mature crRNAs (Brouns et al. 2008). Cleavage is 
achieved by the Cas6 endoribonuclease, a subunit of the Cascade complex with 
repeat-specific activity. Cas6 cleaves the repeat sequence eight nucleotides 
upstream of the spacer sequence, liberating a small crRNA containing a full 
spacer flanked by partial repeats. The crRNA remains associated to Cascade 
and guides the complex to its target. 
     Efficient immunity requires the interaction between the first eight nucleotides 
of the target (a region known as the target “seed”) and the complementary 
sequence of the crRNA guide (Semenova et al. 2011; Wiedenheft et al. 2011) at 
the 5’ end of the DNA:RNA duplex. Viruses containing mutations in this region 
can indeed escape type I CRISPR immunity in E. coli (Semenova et al. 2011). 
Mutations in the sixth nucleotide of the seed are exceptions – they do not affect 
CRISPR immunity. This is due to the noncanonical ribbon structure formed by a 
guide crRNA and its cognate ssDNA target within the Cascade complex. This 
conformation requires outward rotation of every sixth nucleotide in the 
crRNA:ssDNA hybrid (Jackson et al. 2014; Mulepati et al. 2014; Zhao et al. 2014). 
As such, the sixth nucleotide of the seed can remain unpaired without 
compromising the unusual structure, and a mutation at this location does not 
affect immunity.  
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     A second requirement for type I immunity is the presence of a nucleotide motif 
immediately upstream of the target sequence, the protospacer-adjacent motif 
(PAM). For the type I-E system of E. coli the PAM is an AWG trinucleotide and it 
is recognized by CasA, a member of the Cascade complex (Sashital et al. 2012). 
It is believed that the PAM requirement for immunity allows “tolerance to self”: it 
prevents the autoimmunity against the spacer DNA sequences, which are 
complementary to the crRNAs they encode. Absence of a PAM in the 5’ end of 
the target prevents spacer targeting. Similar to the alteration to the seed 
sequence, mutations in the PAM promote the escape of bacteriophages from 
CRISPR immunity (Semenova et al. 2011). 
     If both conditions are met, i.e. base-pairing within the seed and the presence 
of a PAM, recruitment of the Cas3 ssDNA nuclease cleaves and degrades the 
displaced DNA strand within the target sequence (Westra et al. 2012) and 
degrades it with 3’-5’ processivity (Gong et al. 2014; Huo et al. 2014). 
1.2.2 Type II CRISPR-Cas systems 
     Type II CRISPR-Cas systems are defined by the presence of the Cas9 RNA-
guided endonuclease and are the simplest of all CRISPR types (Figure 1-4C). 
Processing of the precursor crRNA does not require a dedicated, repeat-specific 
endoribonuclease. Instead, type II CRISPR loci produce a small trans-encoded 
crRNA (tracrRNA) with a region of complementarity to the repeat sequence 
(Deltcheva et al. 2011). The tracrRNA is bound by the Cas9 nuclease and forms 
a dsRNA interaction with the repeat sequences of the precursor crRNA that is 
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cleaved by RNase III. The result of this reaction is the generation of a Cas9 
enzyme loaded with both the tracrRNA and the crRNA guide, a ribonucleoprotein 
complex that is necessary and sufficient for CRISPR immunity (Sapranauskas et 
al. 2011). 
     Similar to type I, type II CRISPR immunity requires six to eight nucleotides of 
seed sequence (Deveau et al. 2008; Jiang et al. 2013a) as well as a PAM 
(Deveau et al. 2008), which for the Streptococcus pyogenes SF370 type II-A 
CRISPR-Cas system is NGG (Mojica et al. 2009; Jiang et al. 2013a). As opposed 
to type I, however, the seed and PAM sequences are located at the 3’ end of the 
target. As a consequence of these requirements, viruses can escape CRISPR 
immunity by mutating any of these sequences (Barrangou et al. 2007; Deveau et 
al. 2008). Upon infection, the tracrRNA/crRNA/Cas9 ribonucleoprotein complex 
scans the viral genome for the presence of PAM sequences. Binding of Cas9 to 
the PAM favors the unwinding of the target sequence immediately upstream of 
the motif, allowing the crRNA to probe for the presence of a matching sequence 
(Sternberg et al. 2014). A productive annealing results in the formation of a 
crRNA:target R-loop that triggers cleavage by Cas9. The enzyme harbors two 
nuclease domains (HNH and RuvC (Sapranauskas et al. 2011; Jinek et al. 2014; 
Nishimasu et al. 2014)), each of which cuts one target DNA strand. The tracrRNA 
is a co-factor of Cas9 and it is also required for DNA cleavage (Gasiunas et al. 
2012; Jinek et al. 2012). 
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1.2.3 Type III CRISPR-Cas systems 
     Type III CRISPR-Cas systems are possibly the most complex of all CRISPR 
types. These loci are defined by the presence of genes encoding Cas10 and the 
repeat-associated mysterious protein (RAMP) modules Csm or Cmr for type III-A 
or III-B, respectively (Makarova et al. 2011), which together form the Cas10-Csm 
or Cas10-Cmr complexes (Hale et al. 2009; Zhang et al. 2012; Hatoum-Aslan et 
al. 2013). As in type I systems, crRNA precursor processing is achieved by the 
Cas6 repeat-specific endoribonuclease (Carte et al. 2008) (Figure 1-4D). In 
contrast to type I systems, however, Cas6 is not part of the Cas10 complex (Hale 
et al. 2009; Zhang et al. 2012; Hatoum-Aslan et al. 2013), and recent 
experiments suggested that repeat sequences are important to incorporate the 
Cas6 products into the complex prior to targeting (Sokolowski et al. 2014). Also 
in contrast to type I, the crRNAs generated by Cas6 cleavage are further trimmed 
at the 3’ end in a process known as crRNA maturation. Type III crRNA 
maturation eliminates the 3’-end repeat sequences that remain after Cas6 
cleavage and generates a heterogeneous population of mature crRNA guides 
which differ by increments of six nucleotides at the maturation end (Hale et al. 
2008; Hatoum-Aslan et al. 2011). 
     As opposed to the other CRISPR types, a seed sequence has not been 
identified. Moreover, multiple mutations within the target do not abrogate 
immunity (Manica et al. 2013). No PAM requirements have been reported for 
type III targeting either. Instead, the lack of base pairing between the target 5’ 
flanking sequences and the crRNA tag is essential for type III CRISPR immunity 
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(Marraffini 2010). Since there is perfect homology between the upstream repeat 
and the crRNA tag (this is transcribed from the repeat DNA), this property 
enables the discrimination between bona fide targets and the CRISPR array itself 
to avoid autoimmunity. 
     Two unique features of type III CRISPR-Cas systems are (i) that transcription 
across the target is required for immunity (Deng et al. 2013; Goldberg et al. 
2014), and (ii) both DNA (Marraffini and Sontheimer 2008; Manica et al. 2011; 
Goldberg et al. 2014; Samai et al. 2015) and RNA (Hale et al. 2009; Zhang et al. 
2012; Staals et al. 2014; Tamulaitis et al. 2014; Zebec et al. 2014; Samai et al. 
2015) targets are cleaved. In addition, only crRNA guides complementary to the 
coding, but not the template, DNA strand provide effective immunity (Goldberg et 
al. 2014). Because these guides are also complementary to, and cleave, the 
target transcript, type III CRISPR-Cas immunity leads to the co-transcriptional 
destruction of both the target DNA and its transcripts (Peng et al. 2015; Samai et 
al. 2015). Whereas DNA cleavage is essential for immunity, the function of RNA 
targeting is unknown, and has been one of the focuses of my thesis.  
     The transcription requirement allows tolerance of foreign elements that can 
silence the region targeted by type III CRISPR-Cas systems. For example, this 
permits discrimination between the lytic and lysogenic cycles of temperate 
phages. Temperate phages with targets for type III CRISPR immunity within the 
lytic genes, which are expressed only during the lytic cycle but not during the 
prophage stage, can be maintained as prophages inside the cell even if they 
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contain a target that perfectly matches a crRNA (Goldberg et al. 2014). Induction 
of the lytic cycle, however, re-initiates transcription and targeting, and thus type 
III immunity can prevent the lethal reactivation of prophages.  
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CHAPTER 2 APPLICATION OF TYPE II CRISPR-CAS SYSTEM 
IN BACTERIAL GENOME EDITING AND GENE REGULATION 
     In this chapter, I will introduce existing genome editing and gene regulation 
techniques in bacteria and some drawbacks associated with them. I will describe 
the development of type II CRISPR-Cas as a novel sequence-specific counter-
selection tool, and its application in bacterial genome editing and gene regulation. 
Most of this work (Bikard et al. 2013; Jiang et al. 2013a) was done in close 
collaboration with Dr. David Bikard, a previous post-doc in our lab, who’s also a 
great mentor and friend of mine.  
     Since our initial proof-of-principle demonstration of CRISPR-mediated 
genome editing in E.coli and Streptococcus pneumoniae (Jiang et al. 2013a), the 
approach has been successfully applied for genetic manipulation in many more 
bacterial species, including Lactobacillus (Oh and van Pijkeren 2014), 
Clostridium (Wang et al. 2015; Xu et al. 2015), Streptomyces (Cobb et al. 2015; 
Huang et al. 2015), Actinomycetes (Tong et al. 2015), Staphylococcus (Chapter 
2.3.6), Salmonella (in collaboration with Zhenrun J. Zhang, unpublished data) as 
well as bacteriophages (Kiro et al. 2014; Martel and Moineau 2014). CRISPR-
mediated gene regulation has been demonstrated in E.coli (Bikard et al. 2013; Qi 
et al. 2013), Mycobacterium (Choudhary et al. 2015), Bacteroides (Mimee et al. 
2015) and Actinomycetes (Tong et al. 2015). The easy programmability of the 
CRISPR-Cas system greatly facilitated genome editing and modulation of gene 
expression, and is likely to substantially advance our capability to both decipher 
gene function in prokaryotes and manipulate them for biotechnological purposes.  
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2.1 Existing genome editing technology in bacteria 
     Reverse genetics is a powerful approach for identification and understanding 
of gene function. The general methodology consists of first mutation of the gene 
of interest and then analysis of the resulting phenotype. In bacteria, genome 
modification is typically achieved by using allelic replacement (Hamilton et al. 
1989) or λ-Red recombinase-mediated recombination (Court et al. 2002).   
2.1.1 Allelic replacement 
     Allelic replacement (Figure 2-1) is a classical genetic engineering technique 
(Hamilton et al. 1989), and has been extensively used to generate knock-out, 
knock-in or point mutations in chromosomal genes. The method typically makes 
use of temperature-sensitive plasmids, on which a replacing gene fragment with 
homologous sequences flanking the chromosomal gene of interest is cloned. 
Upon introduction to a host such as E.coli and selection of appropriate antibiotic, 
the plasmid can replicate and be maintained at a permissive temperature (e.g., 
30°C). When shifted to a nonpermissive temperature (e.g., 43°C), the plasmid 
can no longer be maintained episomally, and in the presence of the appropriate 
selective antibiotic, homologous recombination between the plasmid-borne 
homology arms and the chromosome results in plasmid integration (Figure 2-1B 
and Figure 2-2A). Since the integrant harbors two sets of homology arms, a 
second recombination event can happen. Because this is usually a low-
frequency event, the plasmid typically carries a counter-selection marker such as 
the sacB gene derived from Bacillus subtilis. Expression of the gene in E.coli is 
lethal in the presence of sucrose (Blomfield et al. 1991), and leads to plasmid 
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excision. Depending on where the second recombination event takes place, the 
chromosome either undergoes a gene replacement or reverts back to the original 
genotype at a roughly 1:1 ratio (Figure 2-1C).  
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Figure 2-1 Genome editing through allelic replacement 
(A) First, a temperature-sensitive plasmid harboring a desired mutation along 
with two homology arms are constructed. The plasmid also carries an antibiotic 
marker (e.g. kan) and a counter-selection marker (e.g. sacB). Upon introduction 
in host cells such as E.coli and selection using kanamycin, the plasmid can be 
maintained at a permissive temperature (e.g. 30°C). (B) When shifted to a 
nonpermissive temperature (e.g., 43°C), the plasmid is forced to integrate into 
the region of the host chromosome carrying the gene of interest (goi) through 
homologous recombination. This low-frequency event can be selected using 
kanamycin. (C) Using a counter-selection marker such as the sacB gene, a 
second recombination event resulting in gene replacement or reversion can take 
place at a roughly 1:1 ratio. Abbreviations: kan, kanamycin-resistant marker; goi, 
gene of interest.  
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Figure 2-2 Genome editing through allelic replacement continued. 
Same as Figure 2-1 except that the initial plasmid integration step can also occur 
through recombination of the right homology arm, as opposed to the left 
homology arm shown in Figure 2-1B.  
     Allelic replacement suffers from some drawbacks. First, it is a two-step 
method that requires cloning, which could be lengthy and labor-intensive. Second, 
the success of the method depends crucially on counter-selection makers. 
Although the sacB sucrose sensitivity system remains the most effective bacterial 
counter-selection tool to date, expression of the gene is harmless in most gram-
positive bacteria and thus cannot support counter-selection in these species 
(Reyrat et al. 1998).  
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2.1.2 λ-Red recombination 
     Bacterial recombineering, first developed in E.coli by Kenan Murphy in 1998 
(Murphy 1998), is a genetic engineering technique that uses phage-encoded 
homologous recombination systems to recombine linear DNA fragments into 
bacterial chromosomes (Court et al. 2002). In contrast to classical techniques 
such as allelic replacement, recombineering is a single-step procedure that does 
not require laborious construction of plasmids containing homology arms (Figure 
2-1). Instead, all that is required is synthesis of standard oligonucleotides (oligos) 
that provide the homology. These oligos can be used directly or for the making of 
PCR products that are used for recombineering.   
     Recombination systems encoded by either redαβδ from phage λ (Murphy 
1998; Yu et al. 2000) or recE/recT from Rac prophage (Zhang et al. 1998) can 
mediate efficient recombination of linear DNA fragments. Now widely used in 
E.coli, the λ-Red system is composed of three λ genes: exo, bet and gam, which 
encode the Exo, Beta and Gam proteins, respectively (Figure 2-3A). When a 
linear dsDNA fragment carrying short sequences of homology on each end is 
introduced to host cells, λ Exo, an exonuclease, degrades the dsDNA in a 5’ to 3’ 
direction (Little 1967; Carter and Radding 1971). As Exo is highly processive 
(Matsuura et al. 2001), the current model suggests that the protein binds one of 
the two dsDNA strands and degrades that strand completely (Figure 2-3B) 
(Mosberg et al. 2010; Pines et al. 2015). The ssDNA generated is then stably 
bound by λ Beta (Figure 2-3D). The function of λ Beta is to protect the DNA from 
single-strand nuclease attack and promote annealing of the exogenous DNA to 
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the complementary ssDNA sequences in the chromosome (Kmiec and Holloman 
1981; Muniyappa and Radding 1986; Karakousis et al. 1998). Specifically, the 
recombination of the ssDNA intermediate preferentially occurs at the lagging 
strand of the replication fork during DNA replication (Figure 2-3D) (Ellis et al. 
2001). The third protein, λ Gam, confers the full recombination potential to the 
system. Gam inhibits RecBCD (Karu et al. 1975; Murphy 1991), host nucleases 
that would otherwise rapidly degrade cellular linear dsDNA (Figure 2-3B). 
ssDNAs on the other hand, are not substrates for RecBCD. Therefore, ssDNA 
fragments can be recombined to the host genome with the presence of only λ 
Beta (Figure 2-3C) (Ellis et al. 2001). Recombineering with ssDNA is more 
efficient than with dsDNA and is the method of choice to create point mutations.  
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Figure 2-3 Genome editing through λ-Red recombination 
(A) The λ-Red recombination system comprises of the Exo, Beta and Gam 
proteins from phage λ. Both linear ssDNAs and dsDNAs can be used as 
substrates for recombination. (B) When a linear dsDNA fragment is introduced to 
host cells, λ Exo degrades the dsDNA in a 5’ to 3’ direction and generates a 
ssDNA. In the meantime, λ Gam protects the dsDNA from degradation by 
inhibiting host nucleases RecBCD. Red segments on DNAs denote new 
sequences to be incorporated and gray segments denote short sequences 
homologous to host chromosomes. (C) Recombination of ssDNA fragments does 
not require λ Exo and Gam. (D) λ Beta binds the ssDNA fragments, protects 
them from single-strand nuclease attack and promotes annealing of the DNA 
preferentially to the lagging strand of the replication fork. (E) Among recombined 
cells, another round of cellular replication is required to complete the synthesis of 
the newly introduced modification on the opposite strand. This results in 50% of 
the recombined cells inheriting the change. Abbreviations: dsDNA, double-
stranded DNA; ssDNA, single-stranded DNA. 
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     The single-step λ-Red recombination system integrates linear DNA fragments 
into the host chromosomes, which circumvents the need for the extensive in-vitro 
cloning that conventional genetic engineering techniques entail. Although the 
system substantially simplifies genome editing, currently it has only been shown 
to work in a limited number of species. These species include E.coli (Datsenko 
and Wanner 2000), Salmonella (Karlinsey 2007), Streptomyces (Gust et al. 2004) 
and Mycobacterium (van Kessel and Hatfull 2008). Additionally, when the 
intention is to create point mutations, the recombineering technique suffers from 
a big downside – lack of selection. Typically recombinants are found in only 0.01% 
of the treated cells if dsDNA is used or 0.1% if cells are treated with ssDNA 
(http://redrecombineering.ncifcrf.gov/) (Yu et al. 2000; Ellis et al. 2001), and thus 
screening of a large number of colonies is required. 
2.2 Existing gene modulation tools in bacteria 
     Unlike eukaryotic cells that can be modulated by RNAi (Hannon and Rossi 
2004), methods for gene regulation are limited in bacteria. Two existing tools for 
gene repression and activation are small antisense RNAs (sRNAs) (Storz et al. 
2011) and DNA-binding transcription activators (Ptashne and Gann 1997).  
2.2.1 Small-RNA-mediated gene repression in bacteria 
     RNA elements are important regulators for gene expression in all domains of 
life. In bacteria, one such regulator comprises riboswitches, which are cis-
elements that modulate the translation of the mRNAs harboring them (Waters 
and Storz 2009). Another class of regulators naturally found in bacteria is small 
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RNAs (sRNA). Typically 50-300 nucleotides long and often trans-encoded, these 
sRNAs usually negatively control translation and stability of target mRNAs by 
base-pairing (Waters and Storz 2009; Storz et al. 2011). Inhibition of translation 
is achieved by base-pairing at or near ribosome binding sites (RBS) and 
occlusion of ribosomes (Figure 2-4A). Base-pairing between the sRNAs and the 
coding region of mRNA recruits RNase E that degrades the target mRNA, 
leading to downregulation of the gene (Figure 2-4B). In many cases, the RNA 
chaperone Hfq is required for the function and/or stability of the trans-encoded 
sRNAs (Figure 2-4A, B and C) (Vogel and Luisi 2011).  
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Figure 2-4 Small RNAs mediate gene repression 
(A) Small RNA (sRNA) in association with the RNA chaperone, Hfq can repress 
gene expression by base-pairing at or near ribosome binding sites (RBS) of its 
target mRNA, which occludes ribosomes from binding and initiating translation. 
(B) sRNA/Hfq complex base-pairs with the coding region of mRNA and recruits 
RNase E, which degrades the target mRNA and leads to downregulation of the 
gene. (C) Hfq may protect some sRNAs from degradation by ribonucleases such 
as RNase E. This figure is adapted from (Vogel and Luisi 2011).  
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     Though the programmable nature of trans-encoded-sRNA offers a promising 
possibility to repress gene expression at will, the efficacy of different sRNAs in 
repression has been variable (Man et al. 2011; Sharma et al. 2012). Conceivably, 
the efficacy can be influenced by factors such as the sequence of sRNAs, their 
interaction with Hfq and thus stability in vivo, as well as sequence of target 
mRNAs and their secondary structures. Since no robust design rule currently 
exists, identification of functional sRNAs often requires screening of a library of 
sRNAs (Man et al. 2011; Sharma et al. 2012). This process is laborious and 
severely limits the application of sRNAs as a tool for gene repression.  
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2.2.2 Transcription activation in bacteria 
     In both prokaryotes and eukaryotes, transcription activation is generally 
achieved by DNA-binding activators (Ptashne and Gann 1997). Activators are 
proteins composed of a DNA-binding domain that recognizes and binds specific 
sites on DNA, and an activation domain that recruits transcriptional machinery to 
the DNA (Figure 2-5A). Early work in yeast showed that fusing a DNA-binding 
domain to a subunit of the RNA polymerase II holoenzyme activates transcription 
from a promoter bearing sequences recognizable by the DNA-binding domain 
(Barberis et al. 1995; Farrell et al. 1996; Gaudreau et al. 1997).  
     In E.coli, the RNAP core enzyme consists of subunits of α, β and β’ in the 
stoichiometry α2ββ’ (Burgess 1969) and one of several alternative σ subunits that 
direct the enzyme to specific promoters (Helmann and Chamberlin 1988). An 
additional protein of unknown function, ω, has been categorized as a subunit of 
RNAP based on its co-purification with RNAP (Burgess 1969). On the other hand, 
the cI protein from phage λ is a DNA-binding protein that recognizes the operator 
sequence located on λ DNA (Li et al. 1994). Early studies showed that by 
tethering λcI to α or ω subunit of RNAP, the chimeric protein effectively mediates 
transcription activation of genes bearing the λ operator (Figure 2-5B) (Dove et al. 
1997; Dove and Hochschild 1998). However, one big downside of transcription 
activation is that the recognition sequence on the DNA is determined by the 
activator and fixed. Therefore it requires engineering of the promoter sequence of 
the gene before it can be activated. Overall, this makes the method cumbersome 
and time-consuming.  
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Figure 2-5 Transcription activation in bacteria 
(A) A transcription activator comprises of a DNA-binding domain that recognizes 
and binds specific sites on DNA, and an activation domain, in many cases a 
subunit of the RNA polymerase (RNAP) that recruits RNAP to the DNA. (B) In 
E.coli, by tethering the cI protein of phage λ to the α subunit of RNAP, the 
transcription activator can recruit RNAP to genes bearing the λ operator, thus 
activating transcription.  
2.3 CRISPR-Cas-mediated counter-selection and genome editing 
     As introduced in Chapter 2.1, current bacterial genome editing methods such 
as allelic replacement and λ-Red recombination suffer from a common 
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disadvantage – the limited utility or complete lack of counter-selection markers. 
Therefore there is a need to develop new and easy counter-selection tools that 
can function in a wide range of bacterial species.  
     To date, all three types of CRISPR-Cas systems are reported to cleave DNA. 
Importantly, our lab discovered that when programmed to target the chromosome 
of Streptococcus pneumoniae, CRISPR-Cas causes autoimmunity and kills the 
cells (Bikard et al. 2012). The lethal consequence upon targeting, presumably 
due to inability of the cellular machinery to repair the cleaved DNA, opened up a 
possibility to adopt CRISPR-Cas as a sequence-specific counter-selection tool in 
bacteria, and potentially facilitate genome editing when combined with existing 
methods.  
     Not all types of CRISPR-Cas systems are suitable for repurposing as genetic 
engineering tools. For example, the DNA cleavage activity of type I and type III 
crRNA:Cas ribonucleoprotein complexes is not well characterized and the 
biogenesis of crRNA guides requires a specialized Cas endoribonuclease, Cas6. 
In addition, these complexes are composed of multiple protein subunits (Figure 
1-4B and D), increasing the engineering required to make them work in 
heterologous hosts. In contrast, type II CRISPR-Cas systems present a simpler 
mechanism which relies on the crRNA-guided nuclease Cas9, its tracrRNA 
cofactor, and the house-keeping RNase III (Chapter 1.2.2). To further simplify the 
system, the crRNA and tracrRNA can be fused to form a single guide RNA 
(sgRNA) (Jinek et al. 2012). Creation of sgRNA obviates the need for RNase III, 
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which is required for canonical crRNA processing canonically (Deltcheva et al. 
2011). In the work presented below, we used the canonical tripartite system 
consisting of the Cas9 nuclease, its tracrRNA cofactor and its crRNA guide that 
specify the target. In all studied bacterial species (including E.coli, Streptococcus 
pneumoniae, Staphylococcus aureus and Salmonella) we worked with, 
heterologous expression of the tripartite system had programmable DNA 
targeting activity, suggesting that host RNase III or homologous enzymes in 
those species can support crRNA processing and thus CRISPR functionality. It 
remains possible that host RNase III in other species might not support crRNA 
processing, in which case the sgRNA-mediated version of engineering would be 
needed in those species.  
2.3.1 CRISPR-Cas as a sequence-specific counter-selection tool 
     In order to test the feasibility of adapting the type II CRISPR-Cas as a 
counter-selection tool, we chose to work with S. pneumoniae because the 
organism is naturally competent for DNA uptake and the genome can be easily 
modified by linear PCR products provided exogenously (Claverys et al. 2009). 
Using the parental strain, R6, we first constructed strain crR6, in which the non-
essential gene IS1167 is replaced by the CRISPR01 locus of Streptococcus 
pyogenes SF370 along with a kanamycin-resistant marker, aphA-3 (Figure 2-6A). 
This CRISPR-Cas locus encodes tracrRNA, Cas9 and a CRISPR array with six 
spacers. The locus also contains cas1, cas2 and csn2, genes that are involved in 
the adaptation phase (Heler et al. 2014) but are dispensable for targeting. 
Notably, the SF370 Cas9 was later widely repurposed as a robust genome 
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editing tool in both bacteria (Jiang and Marraffini 2015) and eukaryotic cells (Hsu 
et al. 2014). We also constructed two other strains, R68232.5, and R6370.1, in which 
the non-essential srtA gene in R6 is disrupted by a chloramphenicol-resistant 
marker, cat, along with a 0.4 kB sequence derived from streptococcal 
bacteriophages φ8232.5 or φ370.1, respectively (Figure 2-6A). Crucially, the first 
spacer of the CRISPR array matches perfectly to a region on the 0.4 kB 
sequence cloned from both phages (Figure 2-6B). However, CRISPR can only 
target φ8232.5 but not φ370.1 as the protospacer on φ370.1 lacks a functional 
PAM, which is required for Cas9 targeting (see Chapter 1.2.2).  
     Next, we transformed R68232.5, and R6370.1 cells with genomic DNA (gDNA) 
extracted from crR6 cells. If targeting of the chromosome by CRISPR leads to 
cell death, we should expect to recover only R6370.1 transformants. Contrary to 
this expectation, we isolated R68232.5 transformants, albeit with approximately 10-
fold less efficiency than R6370.1 transformants (Figure 2-6C). Transformation of 
genomic DNA from crR6M, a strain lacking cas1, cas2 and csn2 yielded similar 
result (Figure 2-6C), consistent with the notion that these genes are dispensable 
for targeting. Genetic analysis of eight R68232.5 transformants revealed that the 
great majority of them had undergone a double recombination event (Figure 
2-6D). Since the crR6 gDNA contains the wild-type srtA locus, it can recombine 
and replace the φ8232.5 target that would be otherwise recognized by Cas9 and 
lead to cell death. This experiment provides the initial proof that the concurrent 
introduction of a targeting construct (i.e. a type II CRISPR-Cas system composed 
of tracrRNA, crRNA and Cas9 (hereafter referred to as the Cas9 complex) that 
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targets a genomic locus) together with an editing template for recombination into 
the targeted locus, can lead to targeted genome editing.  
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Figure 2-6 CRISPR-Cas as a counter-selection tool: initial proof of principle 
in Streptococcus pneumoniae 
(A) Using Streptococcus pneumoniae R6 as a parental strain, crR6 was 
constructed by replacing the non-essential IS1167 by the CRISPR01 locus of 
Streptococcus pyogenes SF370 along with a kanamycin-resistant marker, aphA-
3. crR6M is a minimal type II CRISPR-Cas system that had cas1, cas2 and csn2
deleted from crR6. Using R6 as a parental strain, R68232.5 and R6370.1 were 
constructed by integrating a 0.4 kB region derived from the streptococcal 
bacteriophages φ8232.5 and φ370.1 in the srtA gene, respectively. This region 
was also fused to a chloramphenicol-resistant marker, cat. (B) The φ8232.5 
protospacer matches perfectly to the crRNA derived from spc1 of the CRISPR 
locus. The PAM is TGG. (C) Transformation of donor crR6 and crR6M genomic 
DNA in recipient cells, R68232.5 and R6370.1. As a control of cell competence a 
streptomycin-resistant gene was also transformed. Transformation efficiency was 
measured as the number of colony-forming units (CFU) per μg of donor DNA 
(mean ± SD of three replicas). (D) PCR analysis of eight R68232.5 transformants 
with crR6 genomic DNA. Primers that amplify the srtA locus were used for PCR. 
7/8 genotyped colonies replaced the R68232.5 srtA locus (~3.5 kB) by the wild-type 
locus (~2.2 kB) from the crR6 genomic DNA. Abbreviations: PAM, protospacer 
adjacent motif; Kan, kanamycin; Strp, streptomycin.  
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     CRISPR-mediated killing also works in E.coli (Figure 2-7A). We constructed a 
plasmid, pCas9, which contained tracr and cas9. We also cloned pCRISPR::Ø 
and pCRISPR::rpsL, which were plasmids harboring either an empty spacer, or a 
spacer that matched the rpsL gene on the genome, respectively. When these two 
plasmids were transformed into E.coli cells that already carried pCas9, the 
number of pCRISPR::Ø transformants was over three orders of magnitude more 
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than that of pCRISPR::rpsL (Figure 2-7B). In addition, genetic analysis of eight 
pCRISPR::rpsL transformants revealed that all had deleted the spacer (Figure 
2-7C). These data suggests that CRISPR targeting of host chromosome leads to 
cell death, a property that can be exploited as a powerful tool for counter-
selection. 
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Figure 2-7 CRISPR-Cas as a counter-selection tool in E.coli 
(A) pCRISPR::Ø and pCRISPR::rpsL are kanamycin-resistant plasmids that 
carried either an empty spacer or a spacer that matched the rpsL gene on the 
E.coli genome. These plasmids were transformed into an E.coli strain HME63 
that already harbored pCas9, which contained tracr and cas9. (B) Transformation 
of the pCRISPR::Ø or pCRISPR::rpsL plasmids into HME63 competent cells. 
Transformation efficiency was measured as the number of colony-forming units 
(CFU) per mL of competent cells (mean ± SD of three replicas). (C) PCR 
analysis of eight pCRISPR::rpsL transformants using primers that amplified the 
CRISPR array.  
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2.3.2 Analysis of targeting requirement by Cas9 complex 
     To use the Cas9 complex as a counter-selection tool for genome editing, one 
must design an editing template carrying mutations that abolish cleavage by it, 
thereby preventing cell death. This is easy to achieve when the target to be 
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recognized by CRISPR is deleted or replaced by another sequence. When the 
goal is to generate gene fusions or single-nucleotide mutations, the prevention of 
cleavage by Cas9 is possible only by introducing mutations in the editing 
template that alter either the PAM or the protospacer sequences. To determine 
the constraints imposed by these sequences, we performed a thorough analysis 
of PAM and protospacer mutations that abrogate targeting by Cas9 complex.   
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Figure 2-8 Analysis of targeting requirement by Cas9 complex 
(A) The crRNA derived from spc1 of the crR6 CRISPR locus targets the φ8232.5 
protospacer containing a perfect match and a functional PAM, TGG. (B) 
Genomic DNA from R68232.5 was used as a template to obtain a randomized PAM 
or protospacer library. This was achieved by PCR with primers containing these 
randomized sequences. The PCR products were then transformed into crR6 or 
R6 cells followed by chloramphenicol selection. More than 2×105 
chloramphenicol-resistant transformants, carrying inactive PAM or protospacer 
sequences, were combined for amplification and deep sequencing of the target 
region. In (B), single-stranded DNAs were used for illustration but in real 
experiments double-stranded PCR products were used.  
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     Previous studies proposed that S. pyogenes Cas9 requires an NGG PAM 
immediately downstream of the protospacer (Deltcheva et al. 2011; Gasiunas et 
al. 2012; Jinek et al. 2012). However, because only a very limited number of 
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PAM-inactivating mutations have been described thus far (Deltcheva et al. 2011; 
Bikard et al. 2012; Gasiunas et al. 2012; Jinek et al. 2012), we conducted a 
systematic analysis to find all 5-nucleotide sequences following the protospacer 
that eliminate Cas9 cleavage (Figure 2-8). We used randomized 
oligonucleotides to generate all possible 1,024 5-nucleotide PAM sequences in a 
heterogeneous PCR product that was transformed into crR6 or R6 cells. 
Constructs carrying functional PAMs are expected to be recognized and 
destroyed by crR6 but not R6 cells. More than 2×105 colonies were pooled to 
extract DNA for use as templates for the co-amplification of all targets. PCR 
products were deep sequenced and found to contain all 1,024 sequences, with 
coverage ranging from 5 to 42,472 reads (see supplementary materials of (Jiang 
et al. 2013a)). The functionality of each PAM was estimated by the relative 
proportion of its reads in the crR6 sample over the R6 sample. Analysis of the 
first three bases of the PAM clearly shows that the NGG pattern is under-
represented in crR6 transformants (Figure 2-9A). Furthermore, the next two 
bases have no detectable effect on the NGG PAM (see supplementary materials 
of (Jiang et al. 2013a)), demonstrating that the NGGNN sequence is sufficient to 
license Cas9 activity. Partial targeting was observed for NAG PAM sequences 
(Figure 2-9A). Also the NNGGN pattern partially inactivates CRISPR targeting 
(Figure 2-9B, orange and blue sequences), indicating that the NGG motif can 
still be recognized by the Cas9 complex with reduced efficiency when shifted by 
1 bp. These data shed light on the molecular mechanism of Cas9 target 
recognition, and they revealed that NGG (or CCN on the complementary strand) 
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sequences were sufficient for targeting. As an editing strategy, mutation of the 
two “G”s can abolish targeting, though NGG to NAG or NNGGN mutations 
should be avoided. In theory, a given sequence of any di-nucleotide (i.e. the GG 
in the PAM) occurs once every 8 bp in a stretch of perfectly random sequences. 
This means that almost any position of the genome can be targeted by the Cas9 
complex.  
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Figure 2-9 PAM analysis 
(A) Relative proportion of number of reads after transformation of the random 
PAM constructs in crR6 cells (compared to number of reads in R6 transformants). 
The relative abundance of each 3-nucleotide PAM sequence is shown. Severely 
underrepresented sequences (NGG) are shown in red; partially 
underrepresented one, in orange (NAG). (B) Same as (A) except showing the 
relative abundance of the 2nd, 3rd and 4th PAM sequences. Partially 
underrepresented sequences are also shown in blue.  
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     Another way to disrupt the Cas9-complex-mediated cleavage is to introduce 
mutations in the protospacer region of the editing template. It is known that point 
mutations within the “seed sequence” (the 8 to 10 protospacer nucleotides 
immediately adjacent to the PAM) can abolish cleavage by CRISPR nucleases 
(Semenova et al. 2011; Wiedenheft et al. 2011; Jinek et al. 2012). However, the 
exact length of this region is not known, and it is unclear whether mutations to 
any nucleotide in the seed can disrupt Cas9 target recognition. We followed the 
same deep sequencing approach described above to randomize the entire 
protospacer sequence involved in base pair contacts with the crRNA and to 
determine all sequences that disrupt targeting. Each position of the 20 matching 
nucleotides (Deltcheva et al. 2011) in the spc1 target present in R68232.5 cells 
(Figure 2-8A) was randomized, and a library containing the resulting sequences 
was transformed into crR6 and R6 cells (Figure 2-8B). Consistent with the 
presence of a seed sequence, only mutations in the 12 nucleotides immediately 
upstream of the PAM abrogated cleavage by Cas9 (Figure 2-10). However, 
different mutations displayed markedly different effects. The distal (from the PAM) 
positions of the seed (12 to 7) tolerated most mutations and only one particular 
base substitution abrogated targeting. In contrast, mutations to any nucleotide in 
the proximal positions (6 to 1, except 3) prevented cleavage, although at different 
levels for each particular substitution. At position 3, only two substitutions 
affected cleavage activity with different strength. We conclude that, although 
seed sequence mutations can prevent targeting by the Cas9 complex, there are 
restrictions regarding the nucleotide changes that can be made in each position 
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of the seed. Moreover, these restrictions can most likely vary for different spacer 
sequences.  
Figure 2-10 Analysis of the protospacer sequences 
Relative proportion of the number of reads after transformation of the random 
protospacer constructs in crR6 cells (compared to number of reads in R6 
transformants). The relative abundance of each nucleotide for each position of 
the first 20 nucleotides of the protospacer sequence is shown. High abundance 
indicates lack of cleavage by Cas9 complex, that is, an inactivating mutation. The 
gray line shows the level of the wild-type sequence. The dashed line represents 
the level above which a mutation significantly disrupts cleavage (see 
supplementary materials of (Jiang et al. 2013a)). 
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2.3.3 General scheme for the Cas9-complex-mediated counter-selection 
for genome editing 
     Based on the analysis of targeting requirement by the Cas9 complex, we 
describe a Cas9-complex-mediated counter-selection scheme for genome editing 
(Figure 2-11). First, a targeting construct containing a minimal type II CRISPR-
Cas system (i.e. tracr, cas9 and a spacer that matches the genomic region to be 
modified) is designed.  An editing template is designed to carry mutations that 
abolish recognition and cleavage by the Cas9 complex. Preferably, the mutation 
should be deletion or gene replacement that entirely removes the target 
sequence recognized by the crRNA. If this is not feasible, a mutation in the PAM 
or the seed sequence on the protospacer is generally considered. Based on our 
analysis, mutations in the PAM clearly inactivates targeting by the Cas9 complex, 
whereas the effect of single-nucleotide mutations in the protospacer is highly 
dependent on the sequence context and can be difficult to predict. Therefore we 
believe that mutations in the PAM, if possible, should be the preferred editing 
strategy. Alternatively, multiple mutations in the seed sequence are likely to 
abolish cleavage by the Cas9 complex. 
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Figure 2-11 A general scheme for genome editing mediated by the Cas9 
complex 
A targeting construct encoding the Cas9 complex contains a spacer that matches 
a genomic region to be modified. An editing template should contain either 
deletion, replacement, or mutations within the PAM or protospacer of the target 
sequence. Hence, targeting by the Cas9 complex eliminates cells containing the 
wild-type sequence and selects for the newly modified sequence that abolishes 
targeting. Abbreviations: R, repeat; S, spacer; PAM, protospacer adjacent motif.  
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2.3.4 Genome editing in Streptococcus pneumoniae 
Figure 2-12 Methodology for genome editing in S. pneumoniae 
S. pneumoniae crR6Rk contains tracr, cas9, a single repeat (white box) and a 
kanamycin-resistant marker (aphA-3). Genomic DNA from this strain was used 
as a template for PCR with primers designed to introduce a new spacer (green 
box designated with N). The left and right PCRs are ligated using Gibson 
assembly to make the targeting construct. The targeting construct and an editing 
template carrying a desired mutation (red bar), both in the form of dsDNA, were 
co-transformed into strain crR6Rc, which is a strain equivalent to crR6Rk but has 
the kanamycin-resistant marker replaced by a chloramphenicol-resistant marker 
(cat). Selection of kanamycin results in successful editing.  
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     To develop a rapid and efficient method for targeted genome editing in S. 
pneumoniae, we generated crR6Rk and crR6Rc, strains in which spacers can be 
easily introduced by PCR (Figure 2-12). We decided to edit the β-galactosidase 
(bgaA) gene of S. pneumoniae, whose activity can be easily measured (Zahner 
and Hakenbeck 2000). We set out to introduce alanine substitutions of amino 
acids in the active site of this enzyme: R481A (R→A) and N563A,E564A 
(NE→AA) mutations. To illustrate different editing strategies, we designed 
mutations in both the PAM sequence and the protospacer seed. In both cases 
we used the same targeting construct with a crRNA complementary to a region of 
the β-galactosidase gene that is adjacent to a TGG PAM sequence (CCA in the 
complementary strand) (Figure 2-13A). The R→A editing template (Figure 
2-13A) created a three-nucleotide mismatch on the protospacer seed sequence 
(CGT to GCA, also introducing a BtgZI restriction site). In the NE→AA editing 
template (Figure 2-13A) we simultaneously introduced a synonymous mutation 
that creates an inactive PAM (TGG to TTG) along with mutations that were 218 
nt downstream of the protospacer region (AAT GAA to GCT GCA, also 
generating a TseI restriction site). This last editing strategy demonstrated the 
possibility of using a remote PAM to make mutations in places where a proper 
target might be hard to choose. For instance, although the S. pneumoniae R6 
genome (with a 39.7% GC content) contains on average one PAM every 12 bp, 
some PAMs are separated by up to 194 bp (Figure 2-14). Finally we designed a 
ΔbgaA in-frame deletion template of 6,664 bp. In all three cases, co-
transformation of the targeting construct and editing template produced 10-times 
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more kanamycin-resistant cells than co-transformation with a control editing 
template containing wild-type bgaA sequences (Figure 2-13B). We genotyped 
24 transformants (8 for each editing experiment) by PCR, restriction digest and 
DNA sequencing and found that all but one incorporated the desired change 
(Figure 2-13C, D and E). These data indicate that the editing efficiency in S. 
pneumoniae is approximately 90%. The 10% that were not edited were mostly 
CRISPR mutants, primarily caused by the error-prone Gibson assembly of two 
DNA fragments carrying repeat sequences (data not shown). Finally, we 
measured β-galactosidase activity (Zahner and Hakenbeck 2000) to confirm that 
all edited cells displayed the expected phenotype (Figure 2-13F). 
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Figure 2-13 Genome editing in S. pneumoniae 
(A) Nucleotide and amino acid sequences of the wild-type and edited (green 
nucleotides; underlined amino acid residues) bgaA. The protospacer, PAM and 
restriction sites are shown. (B) Transformation efficiency (counted as CFU/mL) of 
cells transformed with targeting constructs in the presence of an editing template 
or control. Error bars, mean ± SD for three replicas. (C) PCR analysis for eight 
transformants of each editing experiment followed by digestion with BtgZI (R→A) 
and TseI (NE→AA). Deletion of bgaA was revealed as a smaller PCR product. (D 
and E) Editing was confirmed by DNA sequencing. (F) Miller assay to measure 
the β-galactosidase activity of wild-type and edited strains. Error bars, mean ± 
SD for three replicas. 
55 
Figure 2-14 Distribution of distances between PAMs 
NGG and CCN are considered to be valid PAMs. Data is shown for the S. 
pneumoniae R6 genome as well as for a random sequence of the same length 
and with the same GC-content (39.7 %). The dotted line represents the average 
distance (12 nt) between PAMs in the R6 genome. 
     Cas9-complex-mediated editing can also be used to generate multiple 
mutations for the study of biological pathways. We decided to illustrate this for 
the sortase-dependent pathway that anchors surface proteins to the envelope of 
Gram-positive bacteria (Marraffini et al. 2006). We introduced a sortase deletion 
by co-transformation of a chloramphenicol-resistant targeting construct and a 
ΔsrtA editing template (Figure 2-15A). Next we introduced a β-galactosidase 
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deletion by co-transformation of a kanamycin-resistant targeting construct that 
replaced the previous one and a ΔbgaA editing template. In S. pneumoniae, β-
galactosidase is covalently linked to the cell wall by sortase (Zahner and 
Hakenbeck 2000). Therefore, deletion of srtA resulted in the release of the 
surface protein into the supernatant, whereas the double deletion had no 
detectable β-galactosidase activity (Figure 2-15B). Such a sequential selection 
can be iterated as many times as required to generate multiple mutations. Finally, 
to eliminate the CRISPR-Cas locus, we introduced a plasmid containing the 
bgaA target and a spectinomycin resistance gene along with genomic DNA from 
the wild-type strain R6. Spectinomycin-resistant transformants that retain the 
plasmid eliminated the CRISPR sequences (Figure 2-15C).  
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Figure 2-15 Sequential introduction of mutations by CRISPR-mediated 
genome editing in S. pneumoniae  
(A) A schematic for sequential introduction of mutations by CRISPR-mediated 
genome editing. First, R6 is engineered to generate crR6Rk. crR6Rk is co-
transformed with a srtA-targeting construct fused to cat for chloramphenicol 
selection of edited cells, along with an editing construct containing a ΔsrtA in-
frame deletion. Strain crR6 ΔsrtA is generated by selection on chloramphenicol. 
Subsequently, the ΔsrtA strain is co-transformed with a bgaA-targeting construct 
fused to aphA-3 for kanamycin selection of edited cells, along with an editing 
construct containing a ΔbgaA in-frame deletion. Finally, the engineered CRISPR 
locus can be erased from the chromosome by first co-transforming R6 DNA 
containing the wild-type IS1167 locus and a plasmid carrying a bgaA protospacer 
(pDB97), and selection on spectinomycin. (B) β-galactosidase activity as 
measured by Miller assay. In S. pneumoniae, this enzyme is anchored to the cell 
wall by sortase A. Deletion of the srtA gene results in the release of β-
galactosidase into the supernatant. ΔbgaA mutants show no activity. (C) PCR 
analysis for eight spectinomycin (spec)-resistant transformants to detect the 
replacement of the CRISPR locus by wild-type IS1167.  
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     These two mutations can also be introduced simultaneously. We designed a 
targeting construct containing two spacers, one matching srtA and the other 
matching bgaA, and co-transformed it with both editing templates at the same 
time (Figure 2-16A). Genetic analysis of transformants showed that editing 
occurred in 6/8 cases (Figure 2-16B). Notably, the remaining two clones each 
contained either a ΔsrtA or a ΔbgaA deletion, suggesting the possibility of 
performing combinatorial mutagenesis using this strategy.  
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Figure 2-16 Multiplex editing in S. pneumoniae 
(A) The ΔsrtA and ΔbgaA in-frame deletion can be performed simultaneously by 
co-transforming a targeting construct that contains two spacers, each targeting 
srtA and bgaA, into strain crR6Rc followed by kanamycin selection. (B) PCR 
analysis of eight transformants to detect deletions in srtA and bgaA loci.   
2.3.5 Genome editing in E.coli 
     We also repurposed the type II CRISPR-Cas system as a counter-selection 
tool to facilitate genome editing in E.coli. Two plasmids were constructed: a 
pCas9 plasmid carrying the tracrRNA, Cas9 and a chloramphenicol-resistant 
marker, and a pCRISPR plasmid carrying the CRISPR array and a kanamycin-
resistant marker (Figure 2-17A). To be able to measure the efficiency of editing 
independently of CRISPR counter-selection, we sought to introduce an A to C 
transversion in the rpsL gene (Figure 2-17B) that confers streptomycin 
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resistance (Hosaka et al. 2004). We constructed a pCRISPR::rpsL plasmid 
harboring a spacer that would guide Cas9 to cleave the wild-type, but not the 
mutant rpsL allele (Figure 2-17C). The pCas9 plasmid was first introduced into E. 
coli wild-type strain MG1655 and the resulting strain was transformed with either 
pCRISPR::rpsL, the targeting construct, or pCRISPR::Ø, which contained a non-
matching spacer serving as a negative control. W542, an editing oligonucleotide 
containing the A →C mutation was also co-transformed (Figure 2-17C). As a 
result, we were able to recover streptomycin-resistant colonies after 
transformation of only pCRISPR::rpsL but not pCRISPR::Ø, suggesting that Cas9 
cleavage induced recombination of the oligonucleotide (Figure 2-17D). However, 
when co-transformed with pCRISPR::rpsL, the frequency of the streptomycin-
resistant colonies (1.0 ×10-7) was two orders of magnitude lower than that of the 
kanamycin-resistant colonies (1.4 ×10-5), which were presumably cells that 
escaped cleavage by Cas9, similar to those found in Figure 2-7C. Therefore, in 
these conditions, cleavage by the Cas9 complex facilitated the recombination of 
the editing template, but with an efficiency that was not enough to select the 
edited cells above the background of “escapers”. 
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Figure 2-17 CRISPR-mediated genome editing in E.coli 
(A) pCas9 plasmid carries tracr, cas9 and a chloramphenicol-resistant marker; 
pCRISPR plasmid carries a CRISPR array and a kanamycin-resistant marker. (B) 
A K42T mutation (A→C on the nucleotide level) conferring streptomycin 
resistance was introduced in rpsL. (C) The targeting construct, pCRISPR::rpsL 
contained a spacer that matched the wild-type, but not mutant rpsL. To perform 
genome editing, this targeting construct or a control construct, pCRISPR::Ø 
(which contains a non-matching spacer) was co-transformed with W542, an 
editing oligonucleotide that contained the A→C mutation, into E.coli MG1655 that 
already harbored pCas9. (D) Fraction of cells that became streptomycin-resistant 
(StrepR) or kanamycin-resistant (KanR) after co-transformation performed in (C). 
Dashed line indicates limit of detection of the assay. (E) Fraction of StrepR 
colony-forming units (CFUs) calculated from total or KanR CFUs. (F) 
Transformation of the pCRISPR::Ø or pCRISPR::rpsL plasmids into HME63 
competent cells in the absence or presence of the W542 oligo.  Transformation 
efficiency was measured as the number of CFU per mL of competent cells. (G) 
Editing of the rpsL gene was confirmed by DNA sequencing. In (D), (E) and (F), 
error bars represent mean ± SD of three replicas. 
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     To improve the efficiency of genome editing in E. coli, we combined our 
CRISPR-Cas system with the λ-Red recombination technology (see Chapter 
2.1.2). The pCas9 plasmid was introduced into the E.coli recombineering strain 
HME63 (Costantino and Court 2003), which contains the Exo, Beta and Gam 
functions of the λ phage. The resulting strain was co-transformed with the 
pCRISPR::rpsL plasmid (or the pCRISPR::Ø control) and the W542 
oligonucleotide (Figure 2-17C). The recombineering efficiency was 5.3×10-5, 
calculated as the fraction of total cells that became streptomycin-resistant when 
the control plasmid was used (Figure 2-17E). In contrast, transformation with the 
pCRISPR::rpsL plasmid and selection with kanamycin increased the percentage 
of edited cells to 65 ± 14 % (Figure 2-17E). Editing efficiency can be also 
calculated in another way. When transformation was performed with the targeting 
construct alone, we found pCRISPR::rpsL transformants were 1.2×102 CFU/mL, 
as opposed to 5.3×102 CFU/mL for transformation performed with both targeting 
construct and editing template (Figure 2-17F). This rendered the editing 
efficiency 77% ((5.3×102 -1.2×102) / 5.3×102), consistent with the efficiency 
calculated from Figure 2-17E. Streptomycin-resistant colonies were confirmed 
for editing by DNA sequencing of the rpsL allele (Figure 2-17G).In sum, these 
data show that CRISPR-Cas can act as a robust counter-selection tool when 
combined with λ-Red recombination. The editing efficiency is drastically boosted 
from 0.1% (without CRISPR-Cas, see Chapter 2.1.2) to 65 ± 14 % (with 
CRISPR-Cas).  
64 
2.3.6 Genome editing in Staphylococcus aureus 
     In both S. pneumoniae and E.coli, linear DNA fragments can be used as 
editing templates due to either natural competence or the presence of phage 
recombineering machineries. However, many other bacteria are not naturally 
competent and recombineering typically do not work in them. In these species, 
introduction of linear DNA fragments are rapidly degraded by the RecBCD or 
homologue complexes and cannot be used as template for genome editing. To 
demonstrate that it’s possible to use the same CRISPR-mediated counter-
selection scheme to facilitate genome editing in these species, I developed a 
system in which the editing template was placed on a temperature-sensitive 
plasmid. It needs to be mentioned since the following work is still under progress, 
the results I showed are qualitative rather than quantitative.  
     I chose to develop a CRISPR-mediated counter-selection system in 
Staphylococcus aureus, the most studied bacterium in our lab yet for which the 
genome editing tool had not been optimized. The existing technology relies on 
allelic replacement of temperature-sensitive plasmids and subsequent counter-
selection (Bae and Schneewind 2006; Monk et al. 2012). As depicted in Figure 
2-18, the counter-selection marker is a secY antisense RNA cloned under a pTet 
promoter inducible by anhydrotetracycline (aTc). Overexpression of the 
antisense RNA represses secY, which encodes a membrane protein that makes 
up the SecYEG translocase essential for bacterial growth and survival (Manting 
and Driessen 2000).  
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Figure 2-18 Allelic replacement in S. aureus 
(A) First, a temperature-sensitive plasmid harboring a desired mutation along 
with two homology arms are constructed. The plasmid also carries a 
chloramphenicol-resistant marker (cat) and a counter-selection marker, an 
inducible secY antisense RNA. Upon introduction to S. aureus and selection of 
chloramphenicol, the plasmid can be maintained at a permissive temperature (i.e. 
30°C). (B) When shifted to a nonpermissive temperature (i.e., 43°C), the plasmid 
is forced to integrate into the region of the host chromosome carrying the gene of 
interest (goi) through homologous recombination. This low-frequency event can 
be selected using chloramphenicol. (C) When applying anhydrotetracylcline (aTc), 
overexpression of the secY antisense RNA (a counter-selection marker) forces 
plasmid excision, resulting in either gene replacement or reversion at a roughly 
1:1 ratio.  
66 
     We and others attempted to perform genome editing in S. aureus following 
these established protocols. However, we encountered hindrance during the 
counter-selection step and were unable obtain edited cells in many cases. In 
order to circumvent this problem, I decided to apply the type II CRISPR-Cas as a 
counter-selection tool. First, I constructed pWJ40, a plasmid carrying the full type 
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II CRISPR-Cas from S. pyogenes and demonstrated heterologous expression in 
S. aureus constituted a functional immune system (Goldberg et al. 2014). Next, 
cas1, cas2 and csn2 were removed from the plasmid, again creating a minimal 
type II system. When programmed to target the S. aureus genome, this minimal 
system effectively killed the cells (Bikard et al. 2014) just as in S. pneumoniae 
and E.coli. After confirming that Cas9 can be used as a counter-selection tool in 
S. aureus, I removed the overexpression element from the original temperature-
sensitive vector. In the new scheme, I introduced pWJ326, a plasmid that carried 
tracrRNA, Cas9 and a crRNA that targets the chloramphenicol-resistant marker 
(cat) in order to achieve counter-selection. As a proof-of-concept (Figure 2-19), I 
managed to delete terS from the ΦNM1 prophage genome in two weeks.  
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Figure 2-19 CRISPR-mediated genome editing in S. aureus 
(A) First, a temperature-sensitive plasmid harboring the terS deletion along with 
two homology arms are constructed. The plasmid also carries a chloramphenicol-
resistant marker (cat). Upon introduction to S.aureus and selection of 
chloramphenicol, the plasmid can be maintained at a permissive temperature (i.e. 
28°C). (B) When shifted to a nonpermissive temperature (i.e., 37°C), the plasmid 
is forced to integrate into the terS region of the host chromosome through 
homologous recombination. This low-frequency event can be selected using 
chloramphenicol. (C) In order to counter-select, pWJ326, a temperature-sensitive 
plasmid containing tracr, cas9 and a cat-targeting spacer was introduced to 
integrant cells, leading to plasmid excision. Gene replacement or reversion 
occurred at a roughly 1:1 ratio. Following successful terS deletion, pWJ326 can 
be readily lost by growing cells at 37°C.  
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     Interestingly, since plasmid excision is normally a low-frequency event, it was 
expected that counter-selection with pWJ326 should yield only a few colonies. In 
contrast, my preliminary results showed that the transformation efficiency of 
pWJ326 was very high, suggesting that CRISPR-induced recombination may be 
higher in S. aureus than it is in E.coli and S. pneumoniae (Chapter 2.3.7). 
Induction of recombination makes CRISPR a superior counter-selection tool in 
the case of genome editing, and it undeniably deserves a close investigation in 
the future. 
2.3.7 Cas9-complex-mediated cleavage actively induces recombination 
     Continuing from Chapter 2.3.5, the fact that we were able to recover 
streptomycin-resistant colonies after transformation of pCRISPR::rpsL but not 
pCRISPR::Ø in E.coli suggests that Cas9-complex-mediated cleavage induced 
recombination of the editing template (Figure 2-17D). However, since this 
recombination efficiency in wild-type E.coli (i.e. MG1655) was too low, we sought 
to better quantify the fold-induction of recombination by CRISPR in the 
recombineering strain HME63. The experimental set-up is the same as 
schematized in Figure 2-17C in which the targeting construct and the editing 
template were co-transformed. When we measured the number of edited cells 
(StrepR CFU) that simultaneously received the targeting constructs (KanR CFU), 
we found that the pCRISPR::rpsL transformants that were resistant to both 
antibiotics were isolated at a frequency of 2.0×10-4, while for pCRISPR::Ø the 
frequency was 3.0×10-5 under the same condition (Figure 2-20A). This means 
Cas9-complex-mediated cleavage induced recombination by 6.7-fold 
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(2.0×10-4/3.0×10-5). A milder induction (2.2-fold) was found in S. pneumoniae 
using an erythromycin-resistant marker (Figure 2-20B). Altogether, the Cas9 
complex not only provided counter-selection, the cleavage by it induced modest 
recombination which aided in genome editing.  
Figure 2-20 CRISPR-Cas induces recombination 
(A) Fraction of total E.coli cells that became both kanamycin-resistant (KanR) and 
streptomycin-resistant (StrepR) after co-transformation of the targeting construct 
(pCRISPR::rpsL or the pCRISPR::Ø control) and editing template (W542) shown 
in Figure 2-17C . (B) Fraction of total S. pneumoniae cells that became both 
kanamycin-resistant (KanR) and erythromycin-resistant (ErmR) after co-
transformation of the targeting construct (CRISPR::erm(stop) or the CRISPR::Ø 
control) and an editing template that confers erythromycin resistance. Error bars, 
mean ± SD of three replicas.  
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2.3.8 Discussion 
2.3.8.1 CRISPR may be a universal counter-selection tool 
     As mentioned in Chapter 2.1, the biggest drawback for existing genome 
editing tools such as allelic replacement and λ-Red recombination is limited utility 
or complete lack of counter-selection markers. Here we developed a system 
consisting of a minimal type II CRISPR-Cas components, i.e. Cas9, tracrRNA 
and crRNA derived from S. pyogenes. Cas9 is a nuclease whose specificity can 
be programmed by a crRNA. Crucially, we showed that the Cas9 complex can 
cleave host chromosome and lead to cell death, hence it can be used as a 
counter-selection tool. We expressed this system heterologously in S. 
pneumoniae, E.coli and S. aureus without codon optimization, and showed by 
programming with different crRNAs, the system can act as a sequence-specific 
counter-selection tool and facilitate genome editing. Furthermore, we and others 
successfully expanded this tool to many more bacterial species, including 
Lactobacillus (Oh and van Pijkeren 2014), Clostridium (Wang et al. 2015; Xu et al. 
2015), Streptomyces (Cobb et al. 2015; Huang et al. 2015), Actinomycetes (Tong 
et al. 2015), Salmonella (in collaboration with Zhenrun J. Zhang, unpublished 
data) as well as bacteriophages (Kiro et al. 2014; Martel and Moineau 2014). 
These works suggest that the type II CRISPR-Cas system is likely to serve as a 
universal counter-selection tool in a wide variety of bacteria. What if heterologous 
expression of the Cas9 complex does not function in some bacteria? As an 
immune system, CRISPR-Cas is present in 40% of eubacteria and 90% of 
archaea (Grissa et al. 2007). Therefore it is possible to exploit bacteria’s 
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endogenous CRISPR-Cas systems for counter-selection. To this end, the more 
naturally-abundant type I and type III CRISPR-Cas may be harnessed for this 
purpose (Li et al. 2016).   
2.3.8.2 The mutation frequency of CRISPR-Cas in the targeting construct 
and its effect on counter-selection 
     In both S. pneumoniae and E. coli, we found that although genome editing is 
facilitated by a co-selection of transformant cells and a modest induction of 
recombination at the target site by Cas9-complex-mediated cleavage, the 
mechanism that contributes the most to editing is the selection against non-
edited cells. Therefore the major limitation of the method is the presence of a 
background of cells that escape CRISPR-induced cell death and lack the desired 
genomic modification. These “escapers” emerged primarily through the deletion 
of the targeting spacer, thus inactivating CRISPR-Cas. In E.coli HME63, the 
frequency of CRISPR mutation occurred at 2.5×10-4, (Figure 2-7B), as 
calculated by taking the ratio of the number of pCRISPR::rpsL transformants 
(1.2×102 CFU/mL) and the pCRISPR::Ø transformants (4.8×105 CFU/mL). This 
means if editing templates are recombined to the host chromosome at a lower 
frequency, CRISPR-Cas no longer effectively counter-selects. For instance, if the 
effective recombination frequency (i.e. basal recombination frequency + induction 
by CRISPR-Cas) is the same as the mutation frequency, then the theoretical 
editing efficiency is 50%; if the effective recombination frequency is ten times 
less, the editing efficiency drops to 9%, etc. The recombination frequency in the 
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recombineering strain of E.coli was 5.3×10-5 and the fold-induction by Cas9 
cleavage was 6.7-fold (Figure 2-20A), resulting in an effective recombination 
frequency of 3.6×10-4. This makes the theoretical editing efficiency 59% (3.6×10-
4/(3.6×10-4 + 2.5×10-4)), which is consistent with experimental efficiency we 
obtained: 65 ± 14 % (Figure 2-17E). 
2.3.8.3 Off-target effect 
     A fundamental aspect of any targeted genome engineering technology is 
target specificity. This is extremely important in eukaryotes since recognition and 
cleavage of off-target sites will lead to the introduction of undesired mutations by 
NHEJ (non-homologous end joining) repair. We think off-target is a much less 
pronounced issue in bacteria. First, the genomes are smaller. Our analysis of 
targeting requirement (Chapter 2.3.2) revealed that the PAM (NGG) and 
sequence of the 12 nucleotides immediately upstream of the PAM were 
important for recognition and cleavage by the Cas9 complex. This means that 
off-target sequence occurs randomly once every 268 Mb (414 Mb) in theory, and 
thus is unlikely to be found in smaller genomes such as the bacterial ones, which 
range from 130 Kb to 14 Mb (Koonin 2012). 
     Second, we demonstrated that cells were killed by CRISPR-Cas when 
programmed with crRNAs targeting the host chromosome, hence counter-
selection. This means if off-target sites exist, it would not be possible to obtain 
even the on-target modification, since the Cas9 complex would cleave the off-
target sites and cause cell death. In other words, if certain genomic modifications 
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are proved to be difficult to obtain through CRISPR counter-selection, one should 
consider the presence of off-target sites as a possible explanation and change 
the design of crRNAs accordingly. In our hands, we found that crRNAs matching 
off-target sites were rare, and can be usually avoided by using the BLAST tool 
provided by NCBI (http://www.ncbi.nlm.nih.gov/). Additionally, we were only able 
to isolate CRISPR mutants but not target mutant after applying CRISPR counter-
selection without the editing template. This means target mutations are indeed 
very rare events. This observation is also supported by the fact that the error-
prone DNA repair pathway, NHEJ, is absent in most bacteria (Pitcher et al. 2007). 
2.4 Dead Cas9 (dCas9) mediates sequence-specific genetic repression 
and activation in bacteria 
     Cas9 has two nuclease domains, RuvC and HNH, each of which cleaves one 
strand within the target DNA (Gasiunas et al. 2012; Jinek et al. 2012). Mutation of 
the active sites of the two domains, D10A and H840A, abolish cleavage but do 
not impair DNA binding. We therefore thought that it may be possible to exploit 
the DNA-binding activity of this Cas9 catalytic site mutant, hereafter referred to 
as “dead” Cas9 (dCas9), to engineer a programmable transcription regulator. As 
a proof-of-concept, we demonstrated in E.coli that tracrRNA and dCas9 when 
guided with a proper crRNA (hereafter referred as the dCas9 complex), act as a 
transcription repressor by preventing the binding of the RNA polymerase (RNAP) 
to promoter sequences or as a transcription terminator by blocking the running 
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RNAP (Figure 2-21). In addition, a fusion between the ω subunit of the RNAP 
and dCas9 allows for programmable transcription activation (Figure 2-21). 
Figure 2-21 A schematic for dCas9-mediated transcription repression 
Plasmid pdCas9 encodes a cas9 mutant containing D10A and H840A 
substitutions (white holes) that abrogate nuclease activity. This catalytically dead 
Cas9 (dCas9), along with tracrRNA and crRNA form a complex. The crRNA 
directs binding of the dCas9 complex to promoter or open reading frame regions 
to prevent RNAP (RNA polymerase) binding or elongation, respectively. 
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2.4.1 dCas9 mediates transcription repression 
     We converted Cas9 into a programmable DNA-binding protein by introducing 
the D10A and H840A mutations in the RuvC and HNH nuclease domains, 
respectively (Jinek et al. 2012). This catalytically “dead” version of Cas9, dCas9, 
was introduced into the pdCas9 plasmid along with the tracrRNA and a minimal 
CRISPR array designed for the easy cloning of new spacers and expression of 
crRNA guides (Figure 2-21) (Jiang et al. 2013a). To evaluate how dCas9 binding 
to the promoter can affect gene expression in E. coli, we constructed a green 
fluorescence protein reporter plasmid (pDB127) carrying the gfp-mut2 gene 
(Cormack et al. 1996) under the control of a promoter designed to carry several 
NGG PAM sequences on both strands.  
     Twenty-two different spacers were engineered to express crRNAs guiding 
dCas9 to different regions of the gfp-mut2 promoter and open reading frame. A 
greater than 100-fold reduction in fluorescence was observed upon targeting of 
regions overlapping or adjacent to the -35 and -10 promoter elements and to the 
Shine-Dalgarno sequence (Figure 2-22A). Targets on both strands showed 
similar repression levels. These experiments suggest that the binding of the 
dCas9 complex to any position within the promoter region prevents transcription 
initiation, presumably through steric inhibition of RNAP binding. In order to 
confirm that repression was due to dCas9 binding to the promoter DNA and not 
an effect of the antisense guide crRNA by itself, we repeated experiments in the 
absence of dCas9. In all cases tested, the fluorescence levels were identical to a 
non-targeting dCas9 control (Figure 2-22B).  
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Figure 2-22 dCas9 mediates transcription repression 
(A) GFP fluorescence of cells expressing dCas9 guided to different regions of the 
gfp-mut2 gene, relative to the fluorescence of cells expressing a non-targeting 
dCas9, was plotted as a function of the position of the target sequence within the 
gene (+1, transcription start). Squares indicate the PAM position, lines the 
extension of complementarity between the crRNA guide and the reporter gene. 
Red and blue lines indicate crRNAs sequences identical to top or bottom DNA 
strand, respectively. The gfp-mut2 gene (green), its promoter, including the -35 
and -10 elements (gray shade), the ribosome binding site (rbs) and the two 
probes (P511 and P510) used for Northern blot in (C) are shown. Error bars, 
mean ± SD of three replicas. (B) Transcription repression in the absence of 
dCas9. GFP fluorescence of cells expressing crRNAs alone (ΔCas9), relative to 
the fluorescence of control cells lacking a targeting crRNA (Ø) was measured. 
Error bars, mean ± SD of three replicas. (C) Northern blot with probes annealing 
either upstream (P511) or downstream (P510) of the T10 and B10 target sites 
using RNA extracted from cells expressing T5-, T10-, B10-guided dCas9 or a 
control strain without a target (Ø). Detection of 5S RNA serves as a control. 
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     To determine whether DNA binding of the dCas9 complex could prevent 
transcription elongation, we directed it to the open-reading frame of gfp-mut2. A 
reduction in fluorescence was observed when both the coding and non-coding 
strands were targeted, suggesting that dCas9 binding could block the elongating 
RNAP (Figure 2-22A). A range of 2.5- to 5-fold reduction in expression was 
observed when the coding strand was targeted (red spacers), while a range of 6- 
to 35-fold reduction was observed when the dCas9 complex was directed to the 
non-coding strand (blue spacers). To directly determine the effects of dCas9 
binding on transcription, we extracted RNA from strains expressing the T5, T10 
or B10 crRNA guides or a non-targeting dCas9 and subjected it to Northern blot 
analysis using probes binding before (P511) or after (P510) the B10 and T10 
target sites (Figure 2-22C). Consistent with our fluorescence measurement, no 
gfp-mut2 transcription was detected when the dCas9 complex was directed to 
the promoter region (T5 target) and lower levels of transcription were observed 
after the targeting of the T10 region. Interestingly, a smaller transcript was 
observed with the P511 probe in cells where the complex binds to the T10 or B10 
target. These species corresponded to the expected size of a transcript that 
would be interrupted by the dCas9 complex (calculated as ~250 or 300 nt 
between the transcription start and the B10 or T10 target sites, respectively). 
This result is a direct indication that the dCas9 complex caused transcription 
termination. In accordance with the pronounced decrease in fluorescence caused 
by B10-bound dCas9 complex, only the truncated gfp transcript, but no full-length 
transcript, was detected with the P511 probe. Altogether, these results 
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demonstrate that directing the dCas9 complex to different gene regions can 
prevent both the initiation and elongation of transcription. Targeting of the non-
coding strand blocks transcription more efficiently than targeting of the coding 
strand, suggesting a more efficient displacement of the elongating RNAP by the 
complex in this configuration. 
2.4.2 dCas9 mediates transcription activation 
Figure 2-23 A schematic for dCas9-mediated transcription activation. 
Transcription activation in E. coli using dCas9 fused to the ω subunit of RNA 
polymerase (RNAP). The dCas9-ω fusion protein is directed to promoter regions, 
and the ω subunit recruits the RNAP by interacting with the β’ subunit. A host 
with a deletion of rpoZ, encoding ω, is used.  
     The dCas9 complex can be also converted into a transcription activator. 
Previous work demonstrated that a fusion between the λcI protein and the RNAP 
omega subunit (ω) can activate transcription by stabilizing the binding of RNAP 
to a promoter bearing an upstream λ operator (Dove and Hochschild 1998). 
Therefore we made both C- and N-terminal fusions between the ω subunit and 
dCas9 (Figure 2-23), generating plasmids pWJ66 and pWJ68, respectively. We 
also expressed different crRNAs to program the binding of both chimeric proteins 
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to four different positions in a constitutive synthetic promoter controlling the lacZ 
gene (Figure 2-24A) in an E. coli strain lacking the gene encoding the ω subunit 
(rpoZ). Using β-galactosidase activity as a reporter, we investigated the effect of 
both chimeras on gene expression. When the binding site was too close to the 
promoter (e.g. Z1 position), we found binding of the chimeras could still lead to 
repression (Figure 2-24B). With binding sites more distant from the promoter, we 
observed a modest increase in β-galactosidase activity; in the best case we 
observed 2.8-fold activation for the dCas9-ω complex (i.e. when ω is fused to the 
C-terminal of dCas9). 
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Figure 2-24 dCas9-ω mediates transcription activation 
(A) Either N- or C-terminal fusions of the ω subunit to dCas9 were directed to 
four positions (Z1-Z4) of the top strand upstream of the -35 element of the lacZ 
gene. (B) lacZ gene expression levels in the different strains were measured as β 
-galactosidase activity (Miller units). Activation is reported as the relative Miller 
units normalized against the units obtained with cells expressing a C-terminal 
dCas9-ω fusion but no crRNA guide (Ø). Error bars indicates mean ± SD of three 
replicas. Asterisks indicate the P-values associated with each measurement 
compared with cells expressing a C-terminal dCas9-ω fusion but no crRNA guide 
(Ø). *P≤0.05; **P≤0.005; ***P≤0.001. 
     We thus decided to further investigate the activation capabilities of dCas9-ω 
when targeted to regions increasingly distant from the -35 promoter element as 
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well as to both DNA strands (Figure 2-25A). To facilitate measurements we used 
a GFP reporter plasmid, pWJ89, with the gfp-mut2 gene under the control of a 
weak biobrick promoter (BBa_J23117) that is preceded by a sequence rich in 
NGG PAM sequences on both strands. Among ten tested binding sites, two 
(specified by W103 and W108 crRNAs, each targeting a different strand) were 
found to strongly activate gfp-mut2 (Figure 2-25B). These were located 45 and 
56 nt away from the -35 element (80 and 96 nt upstream of the transcription start 
site), and provided a 7.2- and 23-fold induction, respectively. A similar level of 
induction was observed when fluorescence is measured at different growth 
phases (data not shown). These data suggest that the dCas9-ω complex can 
induce gene expression when it binds at an optimal distance from the promoter. 
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Figure 2-25 dCas9-ω mediates transcription activation (continued) 
(A) dCas9-ω was directed to ten positions (W101-W110) of both strands 
upstream of the -35 element of the gfp-mut2 gene. (B) GFP fluorescence of cells 
expressing dCas9-ω guided to different positions shown in (A), relative to the 
fluorescence of cells expressing a non-targeting dCas9-ω, was plotted as a 
function of the position of the target sequence within the gfp-mut2 upstream 
region (+1, transcription start). Squares indicate the PAM position, lines the 
extension of complementarity between the crRNA guide and the reporter gene; 
red lines, top strand targets; blue, bottom strand. Error bars, mean ± SD of three 
replicas. (C) Transcription activation of gfp-mut2 containing promoters of three 
different strengths (J23117, J23116 and J23110) by W103- or W108-guided 
dCas9-ω. The relative induction, compared with the fluorescence of cells 
expressing a non-targeting dCas9-ω, is shown. Error bars indicate mean ± SD of 
three replicas. Asterisks indicate the P-values associated with each 




     To test whether dCas9-ω can induce expression of gfp-mut2 under the control 
of stronger promoters, we replaced the weak promoter in pWJ89 (BBa_J23117) 
with promoters of intermediate (BBa_J23116) and high (BBa_J23110) strength 
(Figure 2-25C), generating plasmids pWJ96 and pWJ97, respectively. We 
compared dCas9-ω-mediated activation of gfp expression from the three 
constructs using the W103 and W108 crRNA guides. For both binding sites, all 
three promoters could be induced by the dCas9-ω complex; however the relative 
induction diminished as the promoter became stronger. Altogether, these results 
show that dCas9 can be used to activate gene expression, with the possibility of 
achieving different levels of activation depending on the strength of the targeted 
promoter (the best induction being obtained with weak promoters).  
2.4.3 Discussion 
     Here I described the use of an RNA-guided DNA binding protein, dCas9, to 
either repress or activate genes in E. coli. In this method dCas9 can be directed 
to any region of the bacterial chromosome that is specified by the base-pair 
complementarity between the crRNA guide and the cognate genomic sequence. 
     Repression was achieved by directing the dCas9 complex to either promoter 
or open reading frame regions. While binding of the dCas9 complex to promoters 
prevented transcription initiation, binding to the open reading frame prevented 
elongation, especially when the non-coding strand is targeted. In general, dCas9 
complex mediates stronger repression when directed to the promoter region than 
to the open reading frame. 
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     Compared to sRNA-mediated transcription repression (Chapter 2.2.1), in 
which repression occurs at the mRNA level, CRISPR-mediated repression 
occurs at the DNA level, by either blocking transcription initiation or elongation. 
Being mechanistically different, the CRISPR method can complement the sRNA 
method, and possibly allow researchers to explore new avenues of research that 
were previously untenable. In addition, since many randomly designed crRNA 
guides that target the promoter region can effectively repress gene expression, it 
seems CRISPR-mediated repression can be more reliable and predictable than 
sRNAs (see Chapter 2.2.1). Future studies should thoroughly compare the 
efficacy and predictability of the two methods in parallel.  
     We also converted the dCas9 complex to a transcription activator by fusing 
dCas9 to the ω subunit of RNAP, which was previously shown to provide 
effective recruitment of RNAP (Dove and Hochschild 1998). Contrary to dCas9-
complex-mediated repression, in which directing of the complex by many crRNAs 
to a large region surrounding the promoter (-60 ~ +40) led to strong repression 
(Figure 2-22A), strong activation was only achieved when guiding the dCas9-ω-
complex to a much narrower region spanning from -100 to -75 (Figure 2-25B). 
Among ten tested crRNA guides, only two showed strong activation. This shows 
that activation of a gene of interest will be highly contingent upon the availability 
of PAM sequences in that defined region. Given the strict position requirement 
for gene activation, it may be necessary to harness the power of Cas9 orthologs 
that can recognize different PAM sequences. In a recent study, the Cas9 proteins 
derived from Streptococcus thermophilus, Neisseria meningitidis and Treponema 
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denticola, each recognizing a different PAM, were converted to dCas9. The study 
showed that these dCas9 proteins are orthogonal, and can mediate simultaneous 
targeted gene regulation in bacterial and human cells (Esvelt et al. 2013). 
Another study reported that by applying selection-based directed evolution, the S. 
pyogenes Cas9 can be modified to recognize alternative PAM sequences 
(Kleinstiver et al. 2015). These natural and engineered Cas9 proteins expand 
targetable sequences that are useful for genome editing and gene regulation.  
     A maximum of a 23-fold induction was achieved when directing a crRNA to 
target the bottom strand with a PAM positioned 56 nt upstream of the -35 
element (Figure 2-25B), suggesting this distance may be optimal for activation. 
Still, the level of activation is lower than the reported 70-fold induction by using 
an engineered λ operator and λcI-ω fusion protein (Dove and Hochschild 1998), 
though a side-by-side comparison is lacking. We think that activation can be 
further optimized by changing the protein linker between dCas9 and ω and/or 
testing activation domains other than ω. Importantly, the main advantage of 
CRISPR-mediated gene activation is that it circumvents the need to modify the 
promoter sequence of the gene of interest, as was required for conventional 
transcription activation by a recruitment method such as the λcI-ω fusion.  
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CHAPTER 3 TYPE III CRISPR-CAS SYSTEM 
     Type III CRISPR-Cas systems are defined by the presence of genes encoding 
Cas10 and repeat-associated mysterious protein (RAMP) modules Csm or Cmr 
for type III-A or III-B sytems, respectively (Makarova et al. 2011), which together 
form the Cas10-Csm or Cas10-Cmr complexes (Hale et al. 2009; Zhang et al. 
2012; Hatoum-Aslan et al. 2013). Among all CRISPR types, the type III systems 
are possibly the most complex. In contrast to type I and type II systems, type III 
CRISPR-Cas displays at least two distinct targeting mechanisms. First, 
transcription across the target is required for immunity. Second, the system 
performs co-transcriptional cleavage of both DNA and RNA targets (see Chapter 
1.2.3). 
     In this chapter, I will describe my published work (Jiang et al. 2016) that 
studies the type III-A system of Staphylococcus epidermidis RP62a (Gill et al. 
2005). Previous work conducted by Gregory Goldberg and Poulami Samai from 
our lab have elucidated key mechanistic questions with regard to co-
transcriptional DNA and RNA cleavage. However, while it is well known that DNA 
targeting is essential for immunity in all types of CRISPR-Cas, the function of the 
RNA-targeting module in type III systems has been elusive. In my research, I 
identified a new CRISPR-associated RNase – Csm6. Along with Csm3, a 
previously characterized RNase, Csm6 plays an important role in type III-A 
CRISPR immunity. In particular, I demonstrated that RNA targeting by one or 
both proteins provides a second line of defense – it is essential for cell survival 
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when target sequences recognized by CRISPR-Cas reside in late-expressed 
phage genes or regions that bear mismatches to the crRNAs.  
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3.1 Functionality of type III-A CRISPR-Cas of Staphylococcus 
epidermidis 
Figure 3-1 The type III-A CRISPR-Cas locus of Staphylococcus epidermidis 
RP62a 
The type III-A CRISPR-Cas locus of Staphylococcus epidermidis RP62a harbors 
three spacers and nine cas genes. cas1 and cas2 are present in most CRISPR-
Cas systems and participate in the adaptation phase. cas6 encodes an 
endoribonuclease that processes the crRNA precursor (pre-crRNA) into small 
crRNA guides. cas10, along with csm2, csm3, csm4 and csm5 encode a protein 
complex responsible for crRNA maturation and targeting. The type III-A system 
cleaves both DNA and RNA when transcription happens across the target. csm6 
is the only gene that has not been characterized in detail.  
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     The type III-A CRISPR-Cas of Staphylococcus epidermidis RP62a harbors 
three spacers and nine cas genes (Figure 3-1) (Gill et al. 2005; Marraffini and 
Sontheimer 2008). The first spacer (spc1) matches a region of the nickase (nes) 
gene found in a staphylococcal conjugative plasmid, pG0400 (Figure 3-2A) 
(Morton et al. 1995). To demonstrate that CRISPR-Cas can act as a defense 
system and that spc1 can prevent plasmid conjugation into S. epidermidis RP62a, 
the CRISPR array was deleted from the chromosome, generating strain Δcrispr 
(Figure 3-2B). As shown in Figure 3-2C and a seminal study by my advisor 
(Marraffini and Sontheimer 2008), wild-type cells were refractory to pG0400 
transfer. The few transconjugants recovered were subjected to thorough 
genotyping and all contained mutation in the CRISPR array or cas genes (Jiang 
et al. 2013b). In contrast, conjugation efficiency was at least three orders of 
magnitude higher in Δcrispr cells (Figure 3-2C). Complementation of pSpc1, a 
plasmid carrying spc1 restored the CRISPR immunity (Figure 3-2C). These data 
indicates that spc1 and the cas genes are involved in preventing plasmid 
conjugation. To further confirmed that the protospacer sequence on pG0400 was 
important for recognition by spc1, the target was introduced with nine silent 
mutations, generating plasmid pG0(mut) (Figure 3-2A) (Marraffini and 
Sontheimer 2008). Indeed, transfer of pG0(mut) was no longer blocked by wild-
type cells, and the conjugation efficiency was as high as that of pG0400 into 
Δcrispr cells (Figure 3-2C).  
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Figure 3-2 Type III-A CRISPR-Cas has anti-plasmid activity 
(A) A staphylococcal conjugative plasmid, pG0400 harbors a protospacer 
sequence that matches Spacer 1 (spc1) of the CRISPR array of Staphylococcus 
epidermidis RP62a. The protospacer sequence was altered to contain nine 
synonymous mutations shown in red, generating plasmid pG0(mut). (B) 
Schematics of the wild-type CRISPR-Cas or Δcrispr locus (harboring deletion of 
the CRISPR array) of Staphylococcus epidermidis RP62a. (C) Conjugation 
experiments were performed by mixing recipient cells carrying different genetic 
background (WT: wild-type; Δcrispr: deletion of CRISPR array; Δcrispr + pSpc1: 
deletion of CRISPR array complemented with spc1 on a plasmid) and donors 
cells carrying pG0400 or pG0(mut). Colony-forming units (CFU) per milliliter (mL) 
values (mean ± SD of three replicas) obtained for recipients and transconjugants 
are shown. Conjugation efficiency (Conj. Eff.) was calculated as the mean 
transconjugants / mean recipients ratio.  
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     Genetic approaches are required to understand the different function of cas 
genes in CRISPR immunity. However, reagents for genetic manipulation such as 
availability of antibiotic markers and efficient transformation/transduction 
methods had been lacking in S. epidermidis. In addition, we were unable to 
identify any bacteriophages, natural immunogens of the CRISPR-Cas system, to 
infect our strain. In order to facilitate future studies of the CRISPR immune 
response, I cloned the entire type III CRISPR-Cas system onto a plasmid, 
generating pWJ30β (Figure 3-3A). I decided to study the plasmid-borne 
CRISPR-Cas in Staphylococcus aureus, a close relative of S. epidermidis that is 
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much more amenable to genetic manipulation. Importantly, a few phages 
capable of infecting S. aureus had been characterized (Bae et al. 2006). The 
plasmid-borne CRISPR-Cas system was functional as an immune system and 
had both anti-plasmid and anti-phage activity (Figure 3-3B and C).  
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Figure 3-3 A plasmid-borne type III-A CRISPR-Cas system is functional in 
Staphylococcus aureus 
(A) The type III-A CRISPR-Cas system of Staphylococcus epidermidis RP62a is 
cloned onto plasmid pC194 (Horinouchi and Weisblum 1982), generating 
pWJ30β, which is subsequently introduced to Staphylococcus aureus RN4220. 
(B) To test functionality of the plasmid-borne CRISPR-Cas system, conjugation 
experiments were performed by mixing recipient cells (RN4220 cells harboring 
pWJ30β or parental plasmid pC194) and donor cells carrying pG0400. Colony-
forming units (CFU) per milliliter (mL) values (mean ± SD of three replicas) 
obtained for recipients and transconjugants are shown. Conjugation efficiency 
(Conj. Eff.) was calculated as the mean transconjugants / mean recipients ratio. 
(C) Functionality of the plasmid-borne CRISPR-Cas system was subjected to 
phage infection assay. First, the CRISPR array of pWJ30β was replaced by 
spacers matching the gp14, gp43 genes of lytic phage ΦNM1γ6 (Goldberg et al. 
2014), and a non-matching spacer (Δcrispr), generating pWJ245, pWJ191 and 
pGG-BsaI-R (Goldberg et al. 2014), respectively. Liquid cultures of RN4220 cells 
harboring these individual plasmids were infected with ΦNM1γ6 (at 0hr). Optical 
density at 600 nm (OD600) was measured for the following 12 hr to monitor cell 
survival. Representative growth curves of at least three independent experiments 
are shown.  
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     The plasmid system I established allowed our lab to investigate the type III 
CRISPR-Cas system more easily. First, a biochemical study performed by a 
former post-doc, Asma Hatoum-Aslan found that Cas10, Csm2, Csm3, Csm4 
and Csm5 can be co-purified with each other in Staphylococcus, suggesting 
these proteins form a complex (Hatoum-Aslan et al. 2013). Next, mature crRNAs 
of various lengths were found to be associated with the complex (Hatoum-Aslan 
et al. 2013). Individual deletion of cas10, csm3 or csm4, but not csm2 or csm5 
abolished complex formation and thus crRNA maturation; deletion of csm2 or 
csm5 individually compromised crRNA maturation (Hatoum-Aslan et al. 2014). 
Moreover, individual deletion of all these genes abrogated anti-plasmid activity, 
suggesting complex formation and crRNA maturation were required for immunity 
(Hatoum-Aslan et al. 2014). The Cas10-Csm::crRNA ribonucleoprotein complex 
(hereafter referred to as Cas10-Csm complex) could be also purified from E.coli, 
and was shown to possess DNA- and RNA-targeting activity specified by the 
sequence of the crRNA in vitro (Samai et al. 2015). These data indicate that 
Cas10, Csm2, Csm3, Csm4 and Csm5 proteins form a complex that is necessary 
for crRNA maturation and targeting (Figure 3-1).  
     Supplementary to the characterization of the Cas10 – Csm5 proteins, it is 
established that Cas1 and Cas2 are involved in the adaptation phase, and are 
dispensable for crRNA biogenesis and targeting (Heler et al. 2014). Cas6 is an 
endoribonuclease that participates in the primary processing of the crRNAs 
(Figure 3-1) (Carte et al. 2008). Since these crRNAs then become the substrates 
for maturation, deletion of Cas6 results in loss of maturation and thus loss of 
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CRISPR immunity (Hatoum-Aslan et al. 2014). The function of csm6 was 
unknown. A genetic study from our lab showed that deletion of the gene 
abolishes anti-plasmid immunity (Hatoum-Aslan et al. 2014). Our lab also 
showed that Csm6 does not co-purify with the Cas10-Csm complex (Hatoum-
Aslan et al. 2013) and that deletion of csm6 does not disrupt crRNA biogenesis 
(Hatoum-Aslan et al. 2011). Therefore it has been proposed that csm6 may be 
involved in the targeting stage of CRISPR immunity.  
3.2 Type III CRISPR-Cas immunity requires transcription 
     The transcription-dependent requirement for type III CRISPR-Cas was first 
discovered by Gregory Goldberg in our lab. Using the plasmid-borne version of 
the S. epidermidis type III CRISPR-Cas (see Chapter 3.1), Gregory designed 
multiple spacers that matched the genome of a dsDNA phage, ΦNM1 (Bae et al. 
2006) (Figure 3-4A). To his surprise, half of the spacers he designed did not 
protect host cells from phage infection (Figure 3-4B). A close examination of the 
orientation of spacers and the phage genome revealed that spacers that confer 
immunity were all antisense to the phage transcripts, while the inactive spacers 
all represented the sense strand. These experiments suggested that successful 
CRISPR immunity may depend on target transcription (Goldberg et al. 2014).  
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Figure 3-4 Transcription is required for the type III-A CRISPR-Cas to target 
phage 
(A) A schematic of the genome of a dsDNA phage, ΦNM1. Twenty spacers that 
matched the top strand (T) or the bottom strand (B) of ΦNM1 were designed and 
the positions of their targets are shown. Green spacers are antisense to the 
phage transcripts, and red spacers have orientations matching the phage sense 
strand. (B) Staphylococcus aureus RN4220 cells harboring plasmid-borne 
CRISPR-Cas are challenged by ΦNM1. The efficiency of plating was used to 
determine immunity against the phage provided by spacers targeting the phage 
regions shown in (A). Dotted line indicates the limit of detection of the assay. 
Error bars indicates mean ± SD of three replicas. Figure is adapted from 
(Goldberg et al. 2014) with modifications. 
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     One of the key experiments that demonstrated transcription-dependent 
targeting is a plasmid-curing assay I developed (Goldberg et al. 2014). In this 
assay, host cells harbored two plasmids (Figure 3-5A). pCRISPR-Cas carried 
the canonical spc1 and all the cas genes, and pTarget contained a target 
sequence cloned after a tetracycline-inducible promoter, Ptet. The two plasmids 
were compatible in the absence of the inducer, anhydrotetracycline (aTc); 
however, when aTc was added, induction of transcription across the target led to 
CRISPR targeting and elimination of the target plasmid (Figure 3-5B). Additional 
evidence such as tolerance of lysogenization, phage escaper analysis and 
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transcriptome analysis (Goldberg et al. 2014) supported the conclusion that 
transcription is required for type III CRISPR-Cas immunity. Moreover, 
biochemical work performed by Poulami Samai in the lab showed that the 
purified Cas10-Csm complex cleaves double-stranded DNA targets only when 
transcription occurs across the target, further corroborating the transcription-
dependent targeting model in vitro (Samai et al. 2015).  
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Figure 3-5 Transcription is required for the type III-A CRISPR-Cas to target 
plasmids 
(A) The plasmid-curing assay used Staphylococcus aureus RN4220 harboring 
two plasmids. pCRISPR-Cas carried the conical spc1 and all cas genes of 
Staphylococcus epidermidis RP62a. pTarget (pWJ153) carried a target sequence 
inserted after a tetracycline-inducible promoter (Ptet). Addition of 
anhydrotetracycline (aTc) induces transcription across the target sequence by 
derepressing the Tet repressor protein (TetR). (B) Agarose gel of linearized 
plasmid DNA purified from aTc-treated (+aTc) and untreated (-aTc) liquid 
cultures at the indicated time points.  
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3.3 Type III CRISPR-Cas targets both DNA and RNA 
     The identity of the target nucleic acid for type III CRISPR-Cas systems was 
controversial at a time. In vivo genetic studies done by our lab showed the type 
III-A system of S. epidermidis targets DNA (Marraffini and Sontheimer 2008; 
Goldberg et al. 2014; Hatoum-Aslan et al. 2014). However, various other groups 
showed that type III-B systems of Pyrococcus furiosus (Hale et al. 2009), 
Sulfolobus solfataricus (Zhang et al. 2012) and Streptococcus thermphilus 
(Zebec et al. 2014) all target RNA in vitro. Therefore, it was thought that the III-A 
and III-B subtypes were functionally different, as the nucleic acids recognized 
and cleaved by the systems are DNA and RNA, respectively. Two subsequent 
reports found that the III-A systems of Streptococcus thermphilus (Tamulaitis et 
al. 2014) and Thermus thermophilus (Staals et al. 2014) also target RNA in vitro, 
further fueling the controversy. However, the aforementioned work conducted by 
Poulami settled the discussion by demonstrating that the type III-A complex of S. 
epidermidis can cleave both DNA and RNA targets, in vitro and in vivo (Samai et 
al. 2015). This finding is reinforced by two subsequent studies, both confirming 
the dual DNA- and RNA-targeting activity of the III-B systems (Elmore et al. 2016; 
Estrella et al. 2016). Poulami’s work also identified active sites within the 
staphylococcal Cas10-Csm complex responsible for DNA and RNA targeting: the 
D586, D587 residues of Cas10 (Figure 3-6) and D32 residue of Csm3 (Figure 
3-7), respectively. Furthermore, mutations that abrogate DNA cleavage did not 
affect RNA cleavage and vice versa, strongly suggesting that DNA- and RNA-
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targeting functions of the Cas10-Csm complex are independent of each other 
(Samai et al. 2015).  
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Figure 3-6 Co-transcriptional DNA cleavage by purified Cas10-Csm 
complex 
(A) Schematic of the co-transcriptional DNA cleavage assay. First, an elongation 
complex (EC) is assembled in the following order: template strand, RNA primer, 
RNA polymerase (RNAP) and non-template strand. Next the purified Cas10-Csm 
complex containing a matching crRNA (derived from spc1) and ribonucleoside tri-
phosphates (rNTPs) are added to the EC to reconstitute the co-transcriptional 
DNA cleavage in vitro. (B, C) Denaturing PAGE and autoradiography of the 
products of two co-transcriptional dsDNA cleavage assays differing in the 
location of the radioactive label: (B) non-template strand; (C) template strand. (D) 
Same as (B) but using a mutant complex containing Cas10D586, D587. Panels (B-D) 
are adapted from (Samai et al. 2015) with modifications. 
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Figure 3-7 RNA cleavage by purified Cas10-Csm complex 
(A) Schematic of the RNA cleavage assay. A 5’ radiolabeled ssRNA substrate is 
mixed with purified Cas10-Csm complex containing a matching crRNA (derived 
from spc1). (B) Reaction products of the RNA cleavage assay are collected at 0, 
1, 2, 3, 4, 5, 7.5, 10, 15, 20, and 30 min, separated by denaturing PAGE and 
visualized by phosphorimaging. (C) Same as (B) but using a mutant complex 
containing Csm3D32A, and the reaction times are 0, 5, 10, 20, 30, 60, 120, 180 
and 240 min. Panels (B) and (C) are adapted from (Samai et al. 2015) with 
modifications. 
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3.4 Discovery of Csm6 as a novel RNase associated with the type III-A 
CRISPR-Cas system 
     csm6 is the least characterized among the cas genes. A previous study by our 
lab showed that deletion of the csm6 abolishes anti-plasmid activity, suggesting a 
potential role in DNA cleavage (Hatoum-Aslan et al. 2014). Contradicting to this 
hypothesis, the Csm6 protein does not co-purify with the Cas10-Csm complex, 
which is sufficient to cleave target DNA in vitro (Samai et al. 2015). A recent 
bioinformatics analysis of the Higher Eukaryotes and Prokaryotes Nucleotide-
binding (HEPN) family reveals that Csm6 is a member of this group and may 
function as a metal-independent RNase (Anantharaman et al. 2013). To test this 
possibility, I expressed Csm6 in E. coli and purified it to homogeneity (Figure 
3-8A). The putative active site double mutant R364A, H369A (Anantharaman et 
al. 2013) was also purified (Figure 3-8A). Incubation of the purified proteins with 
ssRNAs radiolabeled at either end resulted in degradation of the substrate by the 
wild-type Csm6, but not Csm6R364A, H369A or “dead” Csm6 (dCsm6) (Figure 3-8B). 
The reaction did not require any metal cation (Mg, Mn and EDTA were tested 
and obtained the same cleavage; data not shown). I obtained similar results with 
the individual active site mutants (Figure 3-8A), using substrates of different 
sequences and lengths (Figure 3-8C). These results confirmed that Csm6 is a 
metal-independent, sequence-independent RNase.  
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Figure 3-8 RNase activity of Csm6 
(A) Csm6 purification. SDS-PAGE of S. epidermidis Csm6 and its putative active 
site mutants, Csm6R364A and Csm6H369A as well as the double mutant, Csm6R364A,
H369A were purified from E.coli. (B) Purified wild-type Csm6 (WT) and Csm6R364A,
H369A, or “dead” Csm6 (dCsm6) were incubated with a ssRNA substrate (R55) 
radiolabeled at either end. The reaction proceeded for 1 hr and aliquots were 
taken at 0, 5, 15, 30, 45 and 60 min for PAGE and phosphorimager visualization. 
(C) Purified Csm6, Csm6R364A and Csm6H369A were incubated with two different 5’ 
radiolabeled ssRNA substrates of 24 and 55 nucleotides in length (R24 and R55, 
respectively). The reaction proceeded for 1 hr and products were subjected to 
PAGE and visualized by phosphorimaging. “Ø” indicates a control reaction 
without enzyme added. Abbreviations: kDA, kilodalton; nt, nucleotide.  
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     Since previous work proposed that Csm6 participates in DNA targeting 
(Hatoum-Aslan et al. 2014), I tested this idea directly using the plasmid-curing 
assay I previously developed (Figure 3-5). When transcription was induced 
across the target, the pTarget plasmid was equally degraded by both wild-type 
CRISPR-Cas and a Δcsm6 system (Figure 3-9A), suggesting DNA degradation 
does not require csm6. To corroborate this finding, I determined that csm6 is not 
required for targeting of chromosomal DNA (Figure 3-9B). Finally, I tested the 
activity of Csm6 for ssDNA and dsDNA substrates in vitro, but failed to obtain 
any cleavage products (Figure 3-9C). These results demonstrate that Csm6 is 
not involved in DNA targeting. 
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Figure 3-9 Csm6 is not involved in DNA targeting 
(A) Plasmid-curing assay schematized in Figure 3-5A is using plasmids 
harboring a wild-type CRISPR-Cas (WT), a Δcsm6 or a non-targeting CRISPR-
Cas system (Δcrispr). Plasmid DNA was extracted from cells before and after 10 
hr of treatment with the inducer, aTc, linearized and subjected to agarose gel 
electrophoresis. (B) Chromosomal targeting assay. A target sequence (a region 
of the gp43 gene from phage ΦNM1) under the control of a tetracycline-inducible 
promoter, Ptet, was inserted to the chromosome (geh locus) of S. aureus RN4220. 
The target was placed in both orientations with respect to the origin of replication 
(direct and inverted insertions). Orange arrows represent crRNAs. Competent 
cells containing these targets were transformed with different pCRISPR-Cas 
plasmids carrying wild-type CRISPR-Cas (WT), Δcsm6 or Δcrispr (non-targeting 
control), and plated in the presence of the aTc inducer. Co-transcriptional 
cleavage of the target DNA prevents colony formation, presumably through the 
introduction of lethal chromosomal lesions. Transformation efficiency was 
measured as the number of colony-forming units (CFU) per μg of plasmid DNA 
(mean ± SD of three replicas). The dotted line indicates the limit of detection of 
the assay. (C) DNase activity assay for wild-type Csm6. The purified protein was 
incubated either with a 5’ radiolabeled ssDNA oligonucleotide (PS362) or a 
dsDNA substrate obtained by annealing PS362 and PS363. The reaction 
proceeded for 2 hr and aliquots were taken at 0, 15, 30, 45, 60, 90 and 120 min 
for PAGE and phosphorimager visualization. Abbreviations: aTc, 
anhydrotetracycline; kB, kilobase; chr, chromosome; ssDNA, single-stranded 
DNA; dsDNA, double-stranded DNA.  
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     Together with previous reports, the results above show that S. epidermidis 
type III-A CRISPR-Cas system encodes two RNases: a sequence-specific, 
crRNA-guided endoribonuclease, Csm3, and a crRNA-independent ribonuclease, 
Csm6. While it is well established that DNA targeting is required for CRISPR 
immunity, the function of RNases has not been fully explored. One report showed 
that the heterologous expression of the Cas10-Csm complex in E.coli could 
provide immunity against RNA phage MS2 (Tamulaitis et al. 2014). However, 
since RNA phages are rare and a great majority of phages are dsDNA in nature 
(Koonin et al. 2015), the function of RNases merited further investigation.   
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3.5 A challenge for transcription-dependent targeting 
     What is the function of the RNases encoded by the type III CRISPR-Cas 
systems? To answer this question, it’s worth revisiting the biology of phage lytic 
cycles.  As introduced in Chapter 1.1 and recapitulated in Figure 3-10, gene 
expression of many lytic phages is precisely programmed over time. For instance, 
genes that are involved in DNA replication and transcriptional regulation are 
transcribed immediately upon infection. Selective expression of the early genes 
allows phages to replicate at an optimal pace. Genes that encode various phage 
parts are transcribed near and/or after replication is complete, which then 
package the replicated DNA and assemble into hundreds of live phage progenies. 
Two other important late genes encode lysin and holin, which lyse cell walls and 
therefore are toxic to the host. Upon host cell lysis, the phage progeny is 
released and they go on to infect neighboring susceptible cells. 
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Figure 3-10 Phage lytic cycle 
① In general, when a lytic phage infects a cell, it injects its DNA (in this case in a
form of dsDNA) which is quickly circularized. ② Transcription starts. The 
expression of phage genes are temporally regulated. For instance, genes that 
are involved in DNA replication are transcribed early. ③ This allows for phage 
replication. ④ Late genes encode various phage parts, which package the 
replicated DNA and assemble into hundreds of live progenies. ⑤ Two other late 
genes encode lysin and holin. ⑥ These enzymes lyse host bacteria and liberate 
infectious phage progeny.  
     The fact that phage genes are temporally regulated creates a challenge for 
the transcriptional requirement of the type III CRISPR-Cas system. When 
CRISPR spacers target early genes, which are immediately transcribed upon 
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infection, CRISPR can mount an efficient attack while the phage is still at low 
copy number (Figure 3-11A). However, when CRISPR spacers target late genes, 
the infection cycle can proceed unchecked until the target is transcribed. At this 
point, the phage may have already finished replication and host cells may be 
loaded with phage DNA and transcripts (Figure 3-11B). This is a challenge 
because first, CRISPR-Cas may be overwhelmed by the number of target nucleic 
acids inside the cell. Secondly, if CRISPR-Cas is only capable of targeting DNA, 
phage transcripts cannot be restricted and will continue to produce toxic lytic 
enzymes. 
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Figure 3-11 Models for co-transcriptional type III CRISPR-Cas immunity 
when targeting early- and late-expressed phage genes  
(A) When the target (red segment) is located in an early-expressed phage gene, 
type III CRISPR-Cas can act soon upon phage DNA injection and clear infection. 
(B) When the target is located in a late-expressed phage gene, CRISPR-Cas can 
only mount an attack after phage replication. At this stage, host bacteria are full 
of phage DNA and transcripts. Lytic enzymes such as holin and lysin are poised 
to lyse the cell and liberate phage progenies.  
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     Based on these properties of the phage lytic cycle, I hypothesize that (i) when 
type III CRISPR-Cas systems target a late-expressed phage gene, the 
transcriptional requirement for targeting can lead to accumulation of phage DNA 
inside host cells and (ii) in this situation, RNA targeting is required to eliminate 
phage transcripts that would otherwise compromise cell viability.  
3.6 Transcriptional requirement of type III-A CRISPR-Cas targeting leads 
to accumulation of phage DNA 
     To investigate the fate of phage DNA upon infection, I constructed two type 
III-A CRISPR-Cas systems: one with a spacer matching an early-expressed 
phage gene, gp14 (encoding a protein involved in phage DNA replication) and 
the other with a spacer matching a late-expressed gene, gp43 (encoding a phage 
capsid subunit) (Figure 3-12A). Previous transcriptome analysis of S. aureus 
cells infected with lytic phage ΦNM1γ6 in the absence of CRISPR immunity 
confirmed that gp14 is an early gene transcribed between 6 minutes and 15 
minutes after infection while gp43 is a late gene transcribed between 15 minutes 
and 30 minutes after infection (Goldberg et al. 2014). I also used a CRISPR 
system containing a non-matching spacer as a negative control (Δcrispr). In 
addition to these three different type III spacers, I constructed a type II CRISPR-
Cas system of Streptococcus pyogenes (Chapter 2) with a spacer matching gp43 
as a positive control, since it is known that type II CRISPR immunity does not 
require transcription (Gasiunas et al. 2012; Jinek et al. 2012). Next, I infected S. 
aureus cells carrying the four different CRISPR-Cas systems with lytic phage, 
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ΦNM1γ6. To determine the abundance of phage DNA inside host bacteria, I 
extracted total DNA at various time points post infection and subjected them to 
qPCR with primers specific to the phage (Figure 3-12B). For quantification, the 
relative abundance of the phage DNA at 15 minutes post-infection in cells 
harboring the type II system was set as the reference point (i.e. a value of 1). As 
a result of CRISPR immunity, phage DNA was rapidly cleared by the type II 
system and its accumulation was minimal (Figure 3-12B), consistent with a 
previous report showing that phage DNA is immediately degraded upon injection 
by the type II CRISPR-Cas (Garneau et al. 2010). By contrast, in cells harboring 
a non-matching CRISPR-Cas system (Δcrispr), the abundance of phage DNA 
increased dramatically with time (Figure 3-12B), reflecting the progression of 
viral replication during the infectious cycle. Phage DNA clearance by type III 
CRISPR-Cas immunity strongly depended on the region targeted. When the 
early-expressed gene gp14 was targeted, the phage DNA was barely detectable 
(Figure 3-12B). In contrast, when the late-expressed gene gp43 was targeted, 
substantial phage DNA accumulated (Figure 3-12B). For instance, the relative 
abundance at 0.75 hr was 64x (134 divided by 2.1) more than that of the gp14-
targeting cells at the same time point. Phage DNA reached a very high level for 
the first 1.5 hr before it started a slow decline, in contrast to near-instant 
clearance in the gp14-targeting cells. A complete clearance was only achieved 
when cells at 9 hr post-infection were diluted and refreshed in new culture broth 
and grown for an additional 9 hr (Figure 3-12B R9 point).  
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Figure 3-12 Co-transcriptional type III CRISPR-Cas targeting leads to 
accumulation of phage DNA 
(A) A schematic of the genome of lytic phage, ΦNM1γ6. The position of two 
spacers that target gp14 and gp43 is shown. Opposed arrows indicate the 
primers used for qPCR experiments in (B) and Figure 3-13A. (B) qPCR 
performed on the ΦNM1γ6 gp43 gene using total DNA collected from S. aureus 
RN4220 cells carrying different CRISPR-Cas systems at different times post-
infection. Values for the rho gene were used for normalization. The normalized 
value for the measurement at 15 min in cells harboring a type II system was set 
to 1 to obtain the relative abundance of the phage DNA for the rest of the data 
points (mean ± SD of four replicas). The R9 time point indicates that cells were 
refreshed with new culture broth at 9 hr post-infection and were grown for an 
additional 9 hr before collection of DNA for qPCR.  
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     The qPCR was performed with primers that amplify the gp43 target. A similar 
result was obtained when I performed qPCR using primers that amplify the gp14 
target (Figure 3-13A), suggesting that DNA abundance at the target as well as at 
a distant locus is equally affected by CRISPR targeting. Phage DNA 
accumulation was also corroborated by Southern blot analysis (Figure 3-13B, C). 
Whereas phage DNA in cells carrying a type II CRISPR-Cas system was 
minimally detected, it accumulated over the first 90 min of infection cycle in cells 
carrying a type III system targeting the late gp43 gene, with levels similar to 
those determined by qPCR (Figure 3-12B). Interestingly, no cleavage products 
(expected at 2.2 kB and 1.7 kB) were detected. This indicates that cleaved DNA 
may be rapidly degraded by the CRISPR-Cas systems or host nucleases under 
these experimental conditions. 
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Figure 3-13 Corroboration of phage DNA accumulation in vivo 
(A) qPCR performed on the ΦNM1γ6 gp14 gene (Figure 3-12A) using total DNA 
collected from S. aureus RN4220 cells carrying different CRISPR-Cas systems at 
different times post-infection. Values for the rho gene were used for 
normalization. The normalized value for the measurement at 15 min in cells 
harboring the gp14-targeting spacer was set to 1 to obtain the relative 
abundance of the phage DNA for the rest of the data points (mean ± SD of four 
replicas). (B) Schematic showing the location of the EcoRI and PsiI restriction 
sites used to detect phage DNA via Southern blot in (C). The position of the gp43 
target is located 2.2-kB from the EcoRI site and 1.7-kB from the PsiI site. The 
green line indicates the location of the dsDNA probe used in this assay. (C) 
Southern blot on total DNA extracted from cells treated with ΦNM1γ6 at different 
times after infection and digested with EcoRI and PsiI. The intensity, relative to 
cells harboring the type II CRISPR-Cas system, of the 3.9-kb phage fragment is 
reported. 
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     Together these data revealed that the requirement of target transcription for 
type III CRISPR-Cas DNA cleavage results in the accumulation of phage DNA 
when a region that is expressed late in the infectious cycle is targeted. To 
support this finding in vitro, an co-transcriptional DNA cleavage assay 
(schematized in Figure 3-6) with different complex:target molar ratios were 
performed, and target DNA cleavage was detected at a 10:1, but not 1:1, ratio 
(Figure 3-14). This means an excess of target DNA can prevent efficient 
cleavage by the Cas10-Csm complex, suggesting that the accumulation of phage 
DNA found in cells targeting a late gene can be due to the excess of target DNA 
and inefficient CRISPR targeting.  
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Figure 3-14 Co-transcriptional DNA cleavage using different complex:target 
ratios 
Co-transcriptional DNA cleavage of the Cas10-Csm complex and dsDNA target 
at different complex:target ratio. 5 nM of elongation complex (EC) containing a 
radiolabeled dsDNA target, RNA primer and RNA polymerase were incubated 
with 5 or 50 nM of purified Cas10-Csm complex harboring a matching crRNA 
(derived from spc1). Ribonucleoside tri-phosphates (rNTPs) were added to 
initiate transcription and the products of the reactions (30 min after addition of 
rNTPs) were subject to PAGE and phosphorimager visualization.  
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3.7 The biological function of RNases in type III CRISPR immunity 
     In spite of this significant difference in phage DNA accumulation and cleavage 
of the target DNA (Figure 3-12B), both gp14- and gp43-targeting spacers 
protected host bacteria from lytic infection (Figure 3-3C). This raises the 
question as to how lytic phages in great abundance can be in harmony with host 
cells for an extended period of time. It should be pointed out that the phage DNA 
per se does not kill cells. However, host cells are in peril if lytic enzymes encoded 
by the DNA are made in sufficient amount. I therefore hypothesized that the 
RNases of the type III CRISPR-Cas may act as a second line of defense; they 
degrade phage transcripts and prevent translation of toxic proteins when DNA 
targeting is inefficient.  
     As previously mentioned, type III-A CRISPR-Cas systems encode two 
RNases: a sequence-specific, crRNA-guided endoribonuclease, Csm3, and 
another, crRNA-independent ribonuclease, Csm6. Active sites of the two proteins 
were also validated in vitro (Figure 3-7B and Figure 3-8B and C). To test if 
these RNases function in vivo and play a role in immunity, I generated mutant 
CRISPR-Cas systems containing catalytically dead Csm3 (dCsm3), catalytically 
dead Csm6 (dCsm6), or both (dCsm3/dCsm6), respectively. Along with cells 
harboring a wild-type (WT) or a non-matching spacer (Δcrispr), I performed a 
phage infection assay. Total RNAs were extracted at 15, 45 and 90 minutes post-
infection and were subjected to RT-qPCR. When CRISPR targeted the early-
expressed gp14, I did not detect any substantial accumulation of phage 
transcripts in the wild-type, dcsm6, dcsm3 or dcsm3/dcsm6 cells (Figure 3-15A). 
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In contrast, phage transcripts increased dramatically in the absence of immunity 
(Δcrispr) as expected (Figure 3-15A). When I conducted the same experiment 
but targeting the late-transcribed gp43 gene, I observed minor differences 
between target transcripts abundance in wild-type, dcsm3 and dcsm6 strains 
(Figure 3-15B). However, I observed a 50-fold (351 divided by 7) increase in 
viral transcripts in the dcsm3/dcsm6 double mutant, which accumulated similar 
level of phage mRNA as Δcrispr cells 45 minutes after infection (Figure 3-15B). I 
also performed RNA deep sequencing (RNA-seq) in infected cells with the 
different genetic backgrounds. The results confirmed the RT-qPCR data, 
showing that gp14 phage transcripts did not accumulate during the immune 
response of the different CRISPR-Cas systems (Figure 3-15C), but that there 
was a substantial increase in gp43 transcript levels (similar to the Δcrispr control) 
in the dcsm3/dcsm6 double mutant at 45 minutes post-infection (Figure 3-15D). 
Together, these results indicate that the RNase activity of either Csm3 or Csm6 
is required to prevent the accumulation of phage transcripts when the type III-A 
CRISPR-Cas system targets late-, but not early-, expressed phage genes. 
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Figure 3-15 Csm3 and Csm6 are required for the degradation of phage 
transcripts  
(A) RT-qPCR performed on the ΦNM1γ6 gp14 transcript using total RNA 
collected from S. aureus RN4220 cells carrying different type III-A CRISPR-Cas 
systems targeting the gp14 gene at different times post-infection. Values for the 
rho gene were used for normalization. The normalized value for the 
measurement at 15 min in wild-type cells was set to 1 to obtain the relative 
abundance of the gp14 transcript for the rest of the data points (mean ± SD of 
four replicas). (B) Same as (A), but using CRISPR-Cas systems targeting the 
ΦNM1γ6 gp43 gene and measuring relative abundance of the gp43 transcript. (C) 
RNA-seq reads (reads per 500 bases of transcript per million mapped reads, 
RPM) for transcripts in the vicinity of the gp14 target at 15 and 45 min post-
infection of cells harboring different type III-A CRISPR-Cas systems. Vertical 
purple line indicates target position. (D) Same as (C), but showing transcription 
levels in the gp43 target region. Vertical orange line indicates target position. 
     Since it is known that λ-like phages such as ΦNM1γ6 produce long transcripts 
through antitermination mechanisms (Krebs 2010), it is possible to investigate 
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the effect of the RNase activity of Csm3 and Csm6 on phage transcripts further 
away from the target site defined by the crRNA guide (Figure 3-16A). RNA-seq 
of phage transcripts in wild-type, dcsm3, dcsm6 or dcsm3/dcsm6 cells revealed 
that degradation of the phage transcripts extended for at least 1 kB at each side 
of the target site (Figure 3-16B, gp42 and gp44). In particular, a very low level of 
phage transcripts were found in dcsm3 cells, indistinguishable to that of wild-type 
cells. On the other hand, transcript levels in dcsm6 cells were higher. 
Interestingly, this pattern extended 5 kB further downstream, but not upstream 
from the target site (Figure 3-16B). These data suggest that Csm6, and not 
Csm3, is responsible for much of the transcript degradation outside of the target 
region. Since Csm6 is not part of the Cas10-Csm complex (Hatoum-Aslan et al. 
2013), the mechanism by which the RNase activity of Csm6 is first localized to 
the target transcript remains to be elucidated. 
131 
Figure 3-16 Csm6, and not Csm3, degrades phage transcripts in the vicinity 
of the region targeted by the Cas10-Csm complex 
(A) Schematic of the genomic region of ΦNM1γ6 in the vicinity of the gp43 target 
(up to 5 kB upstream and downstream). Vertical colored bars indicate the 100-nt 
window of the RNA-seq data shown in (B). Opposed arrows indicate the primers 
used for RT-qPCR experiments in (C). (B) Total RNA collected from S. aureus 
RN4220 cells carrying different type III-A CRISPR-Cas systems targeting the 
gp43 gene at 45 min post-infection were subjected to RNA-seq. RNA-seq reads 
(reads per 500 bases of transcript per million mapped reads, RPM) for transcripts 
in the regions indicated in (A) were shown. (C) RT-qPCRs using primers shown 
in (A). RT-qPCRs were performed on the ΦNM1γ6 gp37, gp42, gp44 and gp52 
transcripts using total RNA collected from S. aureus RN4220 cells carrying wild-
type, dcsm3/dcsm6 or Δcrispr type III-A CRISPR-Cas systems targeting the gp43 
gene at 45 min post-infection. Values for the rho gene were used for 
normalization. The normalized value for the measurement in wild-type cells was 
set to 1 to obtain the relative abundance of the transcripts in other genetic 
backgrounds (mean ± SD of four replicas).  
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     In light of the results above, I wanted to investigate whether the degradation 
of late-expressed phage transcripts mediated by Csm3 and Csm6 can truly act 
as a second line of defense, i.e., required for CRISPR-Cas immunity during the 
targeting of late genes. To this end, I infected S. aureus cells harboring wild-type 
and RNase-null type III CRISPR-Cas systems and monitored their growth. When 
CRISPR targeted gp14, the mutants dcsm3, dcsm6 and dcsm3/dcsm6 were as 
effective as the wild-type CRISPR-Cas to confer immunity (Figure 3-17A), a 
result that demonstrates the sufficiency of DNA cleavage for viral clearance. In 
contrast, when gp43 was targeted the dcsm3/dcsm6 double mutant failed to 
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provide immunity (Figure 3-17B), similarly to a no-targeting control (Δcrispr). A 
similar result was obtained when I measured the effect of type III-A CRISPR-Cas 
immunity on the propagation of the phage by determining the average burst size, 
i.e. the number of viral particles (counted as plaque forming units, PFU) released 
per infected cells (Figure 3-17C and D). Both experiments indicate that the 
RNase activity of either Csm3 or Csm6 is required for immunity when targeting a 
late-, but not early-, expressed gene. To confirm this temporal pattern I tested 
immunity mediated by dcsm3/dcsm6 mutant systems targeting two other early-
transcribed (gp5 and gp19) and two other late-transcribed (gp50 and gp59) 
genes (Figure 3-17E). Upon infection, targeting of gp5, gp14 and gp19 produced 
efficient immunity, whereas targeting of gp43, gp50 and gp59 resulted in the 
death of bacteria expressing inactive Csm3 and Csm6 RNases (Figure 3-17F). 
These data demonstrate that the RNase activities of Csm3 and Csm6 are 
required for type III-A CRISPR-Cas immunity when the targets specified by the 
crRNA guide reside within late-expressed genes. 
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Figure 3-17 Degradation of phage transcripts by Csm3 and Csm6 enables 
type III CRISPR-Cas immunity targeting late-expressed genes 
(A) S. aureus RN4220 cells carrying different type III-A CRISPR-Cas systems 
targeting the gp14 gene were grown in liquid media and infected with phage 
ΦNM1γ6 phage (at 0 hr) with a multiplicity of infection of five viruses per bacteria 
(MOI = 5). Optical density at 600 nm (OD600) was measured for the following 12 
hr to monitor cell survival. Representative growth curves of at least three 
independent assays are shown. (B) Same as (A), but with the CRISPR-Cas 
systems programmed to target gp43. (C) The different infections performed in (A) 
were plated to enumerate plaque forming units (PFU) and calculate the average 
burst size. Mean ± SD of three replicas are reported. (D) Same as (C), but with 
the CRISPR-Cas systems programmed to target gp43. (E) A schematic of the 
genome of ΦNM1γ6. The position of spacers that target early genes, gp5, gp14 
and gp19, and late genes, gp43, gp50 and gp59 were shown. (F) Survival of cells 
(determined by measuring growth at OD600) carrying dcsm3/dcsm6 type III-A 
CRISPR-Cas systems targeting the different ΦNM1γ6 genes shown in (E). 
Representative growth curves of at least three independent assays are shown. 
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     Why is the RNase activity required when late phage genes are targeted? I 
showed earlier that when CRISPR targeted a late-expressed phage gene, phage 
DNA accumulated inside host bacteria and persisted for a long time (Figure 
3-12B). The experiments performed with the RNase-null systems (Figure 3-15B 
and Figure 3-17B) strongly indicate that degradation of phage transcripts by 
Csm3 and Csm6 limits further viral gene expression and the continuation of the 
lytic infectious cycle, thus allowing for a  “peaceful” co-existence of the phage 
DNA and host bacteria for an extended period of time. To validate the essentiality 
of the RNases and demonstrate that the lingering phage DNA is capable of 
continuing the lytic cycle in the absence of the RNase activity, I designed an 
experiment to eliminate RNase activity 10 hours post-infection, a time when 
phage DNA is still present in host bacteria, and checked for host cell viability. 
First, I infected cells harboring dcsm3/Δcsm6 CRISPR-Cas systems (Δcsm3 is 
not feasible since deletion of the gene results in loss of formation of the Cas10-
Csm complex) targeting gp14 or gp43 and carrying a pCsm6 plasmid, which 
provides aTc-dependent expression of Csm6 (Figure 3-18A). As expected from 
my previous results, in the absence of the inducer the cells targeting gp43, but 
not those targeting gp14, succumbed to phage infection (Figure 3-18B). In the 
presence of aTc, both populations survived (Figure 3-18B). The cells from these 
two populations were washed with fresh broth to eliminate aTc, and thus Csm6 
expression, 10 hours after infection. Cells were diluted in fresh broth with or 
without aTc and their growth was monitored (Figure 3-18C). While the growth of 
gp14-targeting cells was not affected by removal of Csm6, gp43-targeting cells 
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were lysed by phage. This finding corroborates that Csm6 has been keeping the 
accumulated phage DNA “in check” and keep host bacteria alive. Once the 
RNase activity is abrogated, the accumulated phage DNA can continue the lytic 
cycle in spite of DNA cleavage (by Cas10 within the complex), leading to the lysis 
of host bacteria. 
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Figure 3-18 Degradation of phage transcripts by Csm6 enables type III 
CRISPR-Cas immunity against late-expressed genes 
(A) S. aureus RN4220 cells harboring Δcsm6/dcsm3 type III-A CRISPR-Cas 
systems targeting gp14 or gp43 were complemented with a pCsm6 plasmid, 
which carried the csm6 gene under the control of a tetracycline-inducible 
promoter (Ptet). (B) These cells were infected with ΦNM1γ6 (MOI = 5) in the 
presence or absence of the inducer, aTc (0.008 mg/ml), i.e., induction of Csm6 
expression. Bacterial growth was monitored by measuring OD600 for 10 hr. (C) 
The cells grown in the presence of aTc shown in (B) were collected after 10 hr, 
washed to remove residual phages in the supernatant as well as the inducer in 
order to eliminate further expression of Csm6. Washed cells were diluted (1:333) 
in fresh media without phage nor aTc. As a control washed cells were also 
diluted (1:333) in fresh media with aTc (0.008 mg/ml). Bacterial growth was 
monitored by measuring OD600 for 12 hr. 
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3.8 Requirement of Csm6 in providing immunity against phages with 
target mutations 
     So far, my data showed that CRISPR targeting of a late-expressed gene led 
to the accumulation of target DNA. In this scenario the RNase activities of Csm3 
or Csm6 were required to clear the phage transcripts and slow down the phage 
lytic cycle until all DNA targets were destroyed. A similar situation could present 
during infection with phages harboring target mismatches. In both type I and type 
II CRISPR-Cas immunity mutations in the target region lead to the escape of 
mutant phages due to reduced crRNA-guided DNA cleavage. Type III CRISPR-
Cas systems, however, seem much more tolerant of such mutations and are able 
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to provide immunity even in the presence of several mismatches within the 
crRNA:target interaction (Manica et al. 2013; Goldberg et al. 2014). I speculated 
that, if target mutations result in inefficient DNA cleavage also during type III 
CRISPR-Cas immunity, the reported tolerance to mutations could be the result of 
phage transcript cleavage by the Csm3 and/or Csm6 RNase activity, as it is 
known that RNA-RNA binding can be promiscuous. To test this I introduced 3, 4 
and 5 mismatches into the spacer sequence targeting the gp43 gene of ΦNM1γ6 
(Figure 3-19A). I infected hosts carrying these mutations and looked for the 
CRISPR immune response. Consistent with previous reports, type III CRISPR-
Cas immunity protected hosts even in the presence of 3 and 4 mismatches (but 
not 5) between the crRNA guide and its target (Figure 3-19B). I first tested if 
Csm6 was important for immunity in the presence of mismatches by performing 
infections in a Δcsm6 host (Figure 3-19C). Consistent with Figure 3-17B, csm6 
was not required to provide immunity when the phage carried a target with 
perfect homology. However, Δcsm6 cells were not as protected in the presence 
of 3 mismatches and immunity was completely abrogated with 4 mismatches in 
the crRNA:target interaction. Protection in the presence of 4 mismatches 
required the RNase activity of Csm6 but not that of Csm3 (Figure 3-19E). 
     The RNase activity of Csm3 or Csm6 was required for full immunity when 
DNA clearance was slow and inefficient, as was the case when CRISPR-Cas 
targeted late-expressed phage genes. To see if the presence of mismatches 
between crRNA:target can also lead to slow DNA clearance, I performed qPCR 
of the gp43 target to compare phage DNA accumulation during the course of 
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infection of wild-type hosts carrying a perfectly matching or 4-mismatch spacer 
(Figure 3-20A). I observed that indeed the presence of mismatches led to the 
accumulation of target phage DNA. This was corroborated by a plasmid-curing 
assay similar to the one presented in Figure 3-5A (Figure 3-20B, C and D). 
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Figure 3-19 Csm6 is required to provide immunity against viruses with 
target mutations  
(A) Introduction of mutations (in red) in the spacer matching the gp43 gene of 
phage ΦNM1γ6 that generate three, four, or five mismatches in the crRNA:target 
region. (B) S. aureus RN4220 cells that harbored a wild-type III-A CRISPR-Cas 
system targeting the gp43 gene in the presence of different crRNA:target 
mismatches were grown in liquid media and infected with ΦNM1γ6 (at 0 hr) with 
a multiplicity of infection of five viruses per bacteria (MOI = 5). Optical density at 
600 nm (OD600) was measured for the following 12 hr to monitor cell survival. 
Representative growth curves of at least three independent assays are shown. 
(C) Same as (B), but with cells harboring a CRISPR-Cas locus without csm6. (D) 
S. aureus RN4220 cells that carried different type III-A CRISPR-Cas systems 
matching the gp43 gene were grown in liquid media and infected with phage 
ΦNM1γ6 (at 0 hr) with a multiplicity of infection of five viruses per bacteria (MOI = 
5). Optical density at 600 nm (OD600) was measured for the following 12 hr to 
monitor cell survival. Representative growth curves of at least three independent 
assays are shown. (E) Same as (D), but with cells expressing a crRNA with 4 
mismatches. Abbreviation: mm, mismatch.  
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Figure 3-20 Mismatches in crRNA:target leads to accumulation of target 
DNA  
(A) S. aureus RN4220 cells that harbored a wild-type CRISPR-Cas system 
expressing crRNAs with no mismatch (0 mm) or 4 mismatches (4 mm) to the 
target were infected with phage ΦNM1γ6. qPCR was performed on the ΦNM1γ6 
gp43 gene using total DNA collected from cells at different times post-infection. 
Values for the rho gene were used for normalization. The normalized value for 
the measurement at 45 min in 0 mm cells was set to 1 to obtain the relative 
abundance of the phage DNA for the rest of the data points (mean ± SD of four 
replicas). (*) P<0.05; (**) P<0.01. (B) Plasmid-curing assay similar to Figure 
3-5A was performed. pCRISPR-Cas carried a gp43-targeting spacer containing 0 
or 4 mismatches. pTarget (pWJ267) carried a gp43 target sequence inserted 
after a tetracycline-inducible promoter (Ptet). (C) Agarose gel of linearized 
plasmid DNA purified from cells at 0, 10, 30 and 60 min after aTc induction. 
Δcrispr cells were used as a non-targeting control. (D) Agarose gel of linearized 
plasmid DNA purified from cells either before or after 10 hr of treatment with aTc. 
Abbreviation: mm, mismatch. 
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     Target mismatches are not only present within a viral population but are very 
common between related phages. For example, our lab previously engineered a 
spacer matching the gp32 gene present in phage ΦNM1γ6 (Goldberg et al. 2014) 
but simultaneously containing 4 mismatches to the same gene in the related 
phage ΦNM4γ4 (Bae et al. 2006; Heler et al. 2015) (Figure 3-21A). Consistent 
with my results, type III-A CRISPR-Cas immunity against ΦNM1γ6 mediated by 
this spacer does not require the RNase activity of Csm6 (Figure 3-21A and B). 
In contrast, whereas the wild-type CRISPR-Cas system tolerated the 4 
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mismatches and protected cells from ΦNM4γ4 infection, the dcsm6 mutant cells 
were susceptible to viral attack (Figure 3-21A and B). Together with Figure 3-19 
and Figure 3-20, my results show that Csm6 RNase activity is required to 
maintain immunity even in the presence of target mutations that decrease the 
efficiency of DNA targeting, a distinct property of type III systems. 
Figure 3-21 Csm6 is required to provide immunity against viruses with 
target mutations (continued) 
(A) The gp32-targeting spacer matches phage ΦNM1γ6 genome perfectly but 
presents four mismatches in the phage ΦNM4γ4 genome. (B) S. aureus RN4220 
cells that harbored a wild-type, dcsm6 or Δcrispr type III-A CRISPR-Cas system 
targeting the gp32 gene were grown in liquid media and infected with ΦNM1γ6 
(at 0 hr) with a multiplicity of infection of five viruses per bacteria (MOI = 5). 
Optical density at 600nm (OD600) was measured for the following 12 hr to monitor 
cell survival. Representative growth curves of at least three independent assays 
are shown. (C) Same as (B), but following infection with ΦNM4γ4. 
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3.9 Discussion 
     Type III-A CRISPR-Cas systems encode a Cas10-Csm complex that is 
responsible for crRNA biogenesis and targeting. Previous work showed that the 
complex can cleave both the genome and the transcripts of invaders (Peng et al. 
2015; Samai et al. 2015), and that the DNA- and RNA-targeting activity resides in 
Cas10 and Csm3 within the complex, respectively. Here I identified a new 
CRISPR-associated RNase, Csm6, that is not associated with the Cas10-Csm 
complex. I demonstrated that Csm6 has RNase activity both in vitro and in vivo, 
and it plays an important role in CRISPR immunity.  
     Whereas DNA cleavage is fundamental for CRISPR immunity against 
invaders such as phages, a role for the RNase activity of these systems has not 
been determined. Previous works showed that the type III CRISPR-Cas immunity 
requires transcription of the target (Goldberg et al. 2014). This provides a clue, 
as the transcriptional requirement creates a challenge for the type III CRISPR-
Cas system when it targets viral genes that are expressed late in the infection 
cycle. Since CRISPR immunity cannot mount attacks until the phages have 
finished replication in this scenario, the immune system can be overwhelmed by 
the abundance of DNA targets present at this point, and cell viability can be 
compromised. Indeed, my data showed phage DNA accumulates substantially 
when CRISPR targets a late- but not early-expressed gene during infection. 
Under this condition, I showed that the two RNases encoded by the type III-A 
CRISPR-Cas, Csm3 and Csm6 provide a second line of defense. While mutation 
of the active site of either protein alone is not sufficient to break immunity, cells 
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harboring double mutation succumb to phage infection. In contrast, when an 
early-transcribed gene is targeted, DNA cleavage occurs shortly after genome 
injection. In this case the endonuclease activity of the Cas10-Csm complex is 
sufficient to clear the virus; the infectious cycle does not proceed further and I 
showed that degradation of phage transcripts by the two RNases is not 
necessary to prevent phage propagation. 
     Temporal regulation of phage gene expression is universal. I believe that the 
ability of transcript degradation by type III-A CRISPR-Cas systems would be 
important to provide immunity against most classes of dsDNA viruses when the 
crRNA guide targets genes that are expressed late in the infectious cycle. Target 
selection occurs during the “adaptation” phase of CRISPR-Cas immunity, when 
new spacer sequences from an invading phage are incorporated into the 
CRISPR array (Heler et al. 2014). Although little is known about the acquisition of 
spacers by type III CRISPR-Cas systems, type I and II systems incorporate 
spacers matching all regions of the viral genome (Datsenko et al. 2012; Paez-
Espino et al. 2013; Heler et al. 2015), without any noticeable bias towards early 
or late genes. If such bias is also absent during spacer acquisition by type III 
CRISPR-Cas systems, the RNase activity would be necessary to confer 
immunity to all bacteria that incorporate a spacer specifying a late-expressed 
gene. At the moment we do not know the genomic position at which type III-A 
targets are expressed “too late” for viral clearance by the Cas10-Csm DNA 
cleavage activity; i.e., the targeting region at which the Csm3 or Csm6 RNase 
activities are required to rescue the host. I speculate that the onset of phage 
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replication might mark a turning point at which these RNase activities become 
essential. 
     My study showed that either Csm3 or Csm6 RNase activity is required for 
immunity when the target of the Cas10-Csm complex is located in a late-
expressed gene. Mutations in the active sites of either of these genes are not 
sufficient to disrupt immunity. However, in the presence of target mismatches 
that lead to the accumulation of phage DNA, Csm6, but not Csm3, RNase activity 
is required for immunity. How can this be explained? Whereas the RNase activity 
of Csm3 is strictly defined by crRNAs, I showed that Csm6 is a crRNA-
independent nuclease that can degrade transcript at least 1 kB away from the 
target site. Thus, it is conceivable that mismatches between the crRNA and 
target may disrupt activity of Csm3 but not Csm6, a hypothesis that should be 
tested by future experiments. 
     Mismatch tolerance is an important aspect that distinguishes the type III from 
the type I and II CRISPR immune systems. Whereas type I and II CRISPR 
immunity is very sensitive to mutations in the target sequence (especially in the 
“seed” region of the target) (Wiedenheft et al. 2011; Gasiunas et al. 2012; Jinek 
et al. 2012; Westra et al. 2012), type III immunity is unusually tolerant of such 
mutations (Manica et al. 2013; Goldberg et al. 2014), allowing the targeting of 
“escape” or related viruses. In all three systems, target mutations prevent 
efficient DNA cleavage. Here I demonstrated that in type III systems, transcript 
degradation by Csm6 results in robust immunity, presumably by stalling the 
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progression of the phage lytic cycle and allowing for more time for phage DNA 
clearance.  
     Whereas Csm3 is part of the Cas10-Csm complex and cleaves sequences 
that are specified by the crRNA guide (Staals et al. 2014; Tamulaitis et al. 2014; 
Samai et al. 2015), Csm6 is not part of the complex and has sequence-
independent activity. As mentioned above, how Csm6 achieves specificity for 
phage transcripts is not known. In vitro, this RNase performs multiple cleavages 
in RNA substrates of different lengths and sequences, in principle lacking such 
specificity. On the other hand, the Cas10-Csm complex recognizes its RNA 
targets using crRNA guides, thus displaying a sequence specificity that will result 
in the cleavage of phage transcripts by Csm3 when the crRNA derives from a 
phage-matching spacer. Therefore one plausible mechanism to restrict Csm6 
activity to the Cas10-Csm target would be the existence of a transient biophysical 
interaction between them during the targeting stage. This intriguing hypothesis 
should be examined in the future.  
     Another intriguing aspect of Csm6 is its requirement to prevent plasmid 
conjugation (Hatoum-Aslan et al. 2014). Since I found that Csm6 is not involved 
in DNA degradation, I speculate that it may assist the Cas10-Csm complex in the 
clearance of the plasmid DNA by degrading plasmid transcripts, some of them 
possibly important for plasmid replication and maintenance. Additional work 
focused on Csm6 should address question. 
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Figure 3-22 A model for co-transcriptional cleavage of target DNA and its 
transcript during type III-A CRISPR-Cas immunity  
(A) Type III-A CRISPR-Cas cleaves both DNA (by Cas10) and RNA (by Csm3 
and Csm6). Cleavage activity requires target transcription. (B) The role of RNA 
cleavage in type III-A CRISPR immunity. Type III RNases are dispensable when 
CRISPR targets early-expressed phage genes. However, they are required when 
CRISPR targets late-expressed phage genes or when crRNA:target region 
contains mismatches. See text also. Abbreviations: crRNA, CRISPR RNA; RNAP, 
RNA polymerase.  
     In summary, my results allow the formulation of a model for the molecular 
mechanisms underlying type III-A CRISPR-Cas immunity (Figure 3-22). The type 
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III-A Cas10-Csm complex performs co-transcriptional cleavage of the target DNA 
and its transcripts. Within this complex, Cas10 contains the DNase activity and 
Csm3 is an RNase. Csm6 is another type III-A RNase that degrades target 
transcripts. This molecular mechanism of immunity allows for the rapid attack of 
the viral genome when early-expressed targets are specified by the crRNA guide, 
which leads to fast and efficient degradation of the invader’s genetic material and 
the clearance of the infection without the need of RNase activity. In contrast, the 
targeting of late-expressed genes allows viral replication and transcription before 
DNA cleavage can occur. The accumulated genomes are not cleared efficiently 
by the endonuclease activity of the Cas10-Csm complex, and the degradation of 
phage transcripts by Csm3 or Csm6 is required to prevent the completion of the 
infectious cycle and the lysis of the host cell. Similarly, the presence of 
crRNA:target mismatches within the phage population prevents efficient DNA 
cleavage that also leads to the accumulation of phage genomes in the cell. In this 
scenario, the Csm6 RNase is required for transcript degradation and survival. 
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CHAPTER 4 PERSPECTIVES 
     CRISPR-Cas is a sequence-specific adaptive immune system that defends 
prokaryotic cells against infectious viruses. This immune system also acts as a 
barrier to horizontal gene transfer of plasmids and other mobile genetic elements, 
which is a major route through which bacteria exchange beneficial genes such as 
those that encode antibiotic resistance. From a basic science point of view, 
studying CRISPR-Cas can allow scientists to better understand evolution, such 
as the arms race between bacteria and phages, and perhaps discover novel 
methods to prevent the spread of antibiotic resistance. CRISPR-Cas may even 
impact on human health. It is well known that the bacteria living on and inside us, 
known as the human microbiota, play an indispensable role in maintaining 
normal physiological function and providing many benefits for human beings. 
Since CRISPR-Cas is widely present in prokaryotes and protect them from viral 
predation, this immune system may play a role in shaping the bacterial 
population and diversity in this microenvironment.  
     CRISPR-Cas encodes a suite of fascinating molecular machineries such as 
Cas9 that can cleave DNA with incredible precision. The protein has not only 
been developed for genetic manipulation in prokaryotic cells, but also in 
eukaryotic cells (Cong et al. 2013; Mali et al. 2013). Compared to conventional 
targeted genome editing tools such as zinc finger nucleases (ZFNs) (Carroll 2011) 
and transcription activator-like effector nucleases (TALENs) (Joung and Sander 
2013), one of the biggest advantages of the CRISPR-Cas is that sequence-
specificity is determined by small crRNAs or sgRNAs (see Chapter 2.3). Not only 
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are the design and generation of the targeting reagents made much easier, it 
also opens up opportunities to design multiple sgRNAs in order to interrogate 
gene function on a genome-wide scale. Indeed, this is an obvious future direction 
seen by many scientists, as a few independent groups demonstrated that by 
harnessing the cellular NHEJ pathways, Cas9 with a library of sgRNAs can be 
used to generate knockout libraries of human cells. This approach was 
successfully applied to identify genes responsible for drug resistance (Shalem et 
al. 2014; Wang et al. 2014), genes important for bacterial toxicity (Zhou et al. 
2014), and genes conferring resistance to bacterial toxins (Koike-Yusa et al. 
2014). In addition to genome-wide screening, Cas9 has seen scores of 
applications in basic biology, synthetic biology, gene therapy, cancer 
therapeutics, drug development and beyond (Hsu et al. 2014; Jiang and 
Marraffini 2015).  
     We and others also showed that the two nuclease domains of Cas9 can be 
inactivated to make the protein a sequence-specific DNA-binding protein (Bikard 
et al. 2013; Qi et al. 2013). This catalytically dead Cas9, dCas9, can mediate 
transcription repression and activation. As mentioned in Chapter 2.4.3, there are 
similarities and differences between dCas9- and sRNA-mediated gene regulation, 
and future endeavors should be made to compare and contrast the two methods 
in order to discover rules governing the efficacy of repression. The activation of 
gene expression by dCas9 when fused to ω was moderate. Future experiments 
should consider using different activator domains and varying the linker distance 
between the activator and dCas9 to enhance the level of activation. Since dCas9 
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is a sequence-specific DNA-binding protein, this general property can be 
principally exploited to direct any protein of interest to desired locations in the 
genome for many purposes. Indeed, dCas9 was fused to machineries involved in 
epigenetic modification to modulate gene expression (Mendenhall et al. 2013; 
Hilton et al. 2015), or enhanced green fluorescent protein (eGFP) to visualize the 
spatiotemporal dynamics of DNA sequences in living cells (Chen et al. 2013; 
Anton et al. 2014).  
     CRISPR-Cas has three types and three stages (Figure 1-4). Current 
technological development primarily focuses on the targeting stage of the type II 
systems, and this frontier is being extended at a breathtaking speed. What is not 
yet developed? Adaptation is the first stage of the immune system in which cells 
use Cas machineries to integrate foreign DNA or RNA fragments into the host 
chromosome. Given that integrases have been successfully developed as tools 
for site-specific recombination historically, it is highly plausible that the CRISPR 
adaptation machineries can be engineered for technological uses as well. 
Secondly, works performed by us and others revealed that the type III CRISPR-
Cas systems cleave both DNA and RNA, suggesting that these systems may be 
exploited to manipulate RNA molecules. 
     The type III CRISPR-Cas encodes elaborate molecular scissors that cleave 
both DNA and RNA. My work identified Csm6, a new CRISPR-associated 
ribonuclease and elucidated at least one biological function of the RNA cleavage 
– when the activity of DNA cleavage is weakened (i.e. when targeting late-
expressed phage genes or regions bearing mismatches), type III RNases 
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degrade phage transcripts and prevent the production of toxic enzymes, thus 
acting as a second line of defense in addition to the DNA-cleaving module. As 
mentioned in Chapter 3.9 , there are many questions remained to be explored. 
Csm6 is not associated with the Cas10-Csm complex, what is the mechanism 
through which the protein gets recruited to the target transcript, and what is the 
processivity of it? When the crRNA and the target contain mismatches, the 
RNase activity of Csm6 but not Csm3 is required for immunity against phage 
infection. Given that the activity of Csm3 is strictly defined by crRNAs while that 
of Csm6 can be extended to at least 1 kB away from the target site, could this 
mean that mismatches between the crRNA and target disrupt activity of Csm3 
but not Csm6? Csm6 is not involved in DNA degradation, and yet it is required to 
prevent plasmid conjugation. Could this be attributed to its RNase activity 
towards plasmid transcripts essential for replication and maintenance? 
Understanding these fundamental problems can strengthen the current model in 
which the type III RNases function as a second line of defense.   
     Forty years ago, the discovery of restriction enzymes unleashed a revolution 
in modern molecular biology. Today, CRISPR-Cas is driving numerous 
innovative applications from basic biology to biotechnology and medicine. 
Despite being forty years apart, both restriction enzymes and CRISPR-Cas 
systems share remarkably similar pathways. They both originated from basic 
studies of bacterial immune systems that cleave viral DNA, and have 
unequivocally revolutionized biological sciences by facilitating manipulation of 
DNA sequences. Restriction enzymes and CRISPR-Cas systems are testaments 
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to the practical value of studying the microbial world, which harbors a reservoir of 
amazing molecular machineries yet to be discovered.   
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CHAPTER 5 MATERIALS AND METHODS 
5.1 Bacterial strains and growth conditions 
     Cultivation of E.coli strains DH5α, MG1655, HME63 (derived from MG1655, 
Δ(argF-lac) U169 λ cI857 Δcro-bioA galK tyr 145 UAG mutS<>amp) (Costantino 
and Court 2003) and their derivatives was done in LB medium (BD) or Terrific 
Broth medium (Fisher Scientific) at 37 °C. Whenever applicable, media were 
supplemented with ampicillin (100 µg/ml), chloramphenicol (25 µg/ml) or 
streptomycin (50 μg/ml) to ensure plasmid maintenance or selection of rpsL 
mutant cells.  
     Cultivation of S. aureus strain RN4220 (Nair et al. 2011) and derivatives was 
done in TSB medium (BD) at 37 °C unless otherwise indicated. Whenever 
applicable, media were supplemented with chloramphenicol (10 µg/ml) or 
erythromycin (10 µg/ml) to ensure plasmid maintenance. When appropriate, 
anhydrotetracycline (aTc) was used at a concentration of 0.25 µg/ml (unless 
otherwise indicated) to initiate transcription from the Ptet promoter. 
     Cultivation of S. epidermidis strain RP62a (Gill et al. 2005) and derivatives 
was done in BHI medium (BD) at 37 °C. Whenever applicable, media were 
supplemented with 10 µg/ml chloramphenicol or 5µg/ml mupirocin to ensure 
plasmid maintenance.  
     Liquid culture of S. pneumoniae strain R6 (Hoskins et al. 2001) and 
derivatives were grown in THYE medium (30 g/l Todd-Hewitt agar, 5 g/l yeast 
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extract). Plating was done on tryptic soy agar (TSA) medium (BD) supplemented 
with 5% defibrinated sheep blood. When appropriate, media were supplemented 
with kanamycin (400 μg/ml), chloramphenicol (5 μg/ml), erythromycin (1 μg/ml), 
streptomycin (100 μg/ml) or spectinomycin (100 μg/ml) for selection.  
5.2 Bacterial strain construction 
  Construction of E.coli JEN202 was described in (Bikard et al. 2013). 
     Construction of S. pneumoniae strains crR6, R68232.5 and R6370.1 were 
described in (Bikard et al. 2012). crR6M, crR6Rk, crR6Rc, JEN38 and JEN62 
were described in (Jiang et al. 2013a).  
     Construction of S. epidermidis Δcrispr, known as LAM104, was described in 
(Marraffini and Sontheimer 2008). 
5.3 Plasmid Cloning 
5.3.1 Cloning in E.coli 
     Cloning used E.coli DH5α electrocompetent cells. To clone WT Csm6 for 
purification, PCR was performed using pWJ30β (Hatoum-Aslan et al. 2013) as 
template and primers PS11 and PS12. The PCR product was digested with 
restriction enzymes NdeI and XhoI and ligated to the vector pET23a-His6 (C-
terminal) digested with the same enzymes, making plasmid pPS10. The Csm6 
mutants R364A (plasmid pPS42), H369A (plasmid pPS43) and R364A-H369A 
(plasmid pPS44) were constructed using the plasmid pPS10 as a backbone with 
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three sets of primers PS245/PS246, PS243/PS244 and PS247/PS248, 
respectively.  
     Construction of plasmids pCas9, pCRISPR::Ø and pCRISPR::rpsL were 
described in (Jiang et al. 2013a). pdCas9, pDB127, pWJ66, pWJ68, pWJ89, 
pWJ96 and pWJ97 were described in (Bikard et al. 2013). 
5.3.2 Cloning in S. pneumoniae 
  Construction of plasmid pDB97 was described in (Jiang et al. 2013a). 
5.3.3 Cloning in S. aureus 
     Cloning used S. aureus RN4220 electrocompetent cells. For type III-A 
pCRISPR-Cas plasmids, new spacers were cloned by ligation of annealed 
oligonucleotide pairs and BsaI-digested parent vector, pGG-BsaI-R (Goldberg et 
al. 2014). The sequences of the spacers cloned are provided in Table 1. To 
construct Δcsm6 plasmids, PCR was performed using WT plasmid as template 
and primers L342/L343. PCR product was restriction digested with PspOMI and 
EagI (NEB), followed by ligation by T4 DNA Ligase (NEB). To construct dcsm6 
plasmids, PCR was performed using WT plasmid as template and primers 
W852/PS248 and primers PS247/W614. The two PCR products were then 
ligated using Gibson assembly. To construct dcsm3 plasmids, PCR was 
performed using WT plasmid as template and primers W852/PS466 and primers 
PS465/W614. The two PCR products were then ligated using Gibson assembly. 
To construct pCsm6 overexpression plasmid, one PCR was performed using 
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pWJ153 (Goldberg et al. 2014) as template and primers W1129/W1113. Another 
PCR was performed using pWJ30β as template and primers W1127/W1128. The 
two PCR products were then ligated using Gibson assembly.  
     Construction plasmid pG0(mut) was described in (Marraffini and Sontheimer 
2008). Plasmid pSpc1was known as pCRISPR in (Marraffini and Sontheimer 
2008). pWJ30β was described as pcrispr in (Hatoum-Aslan et al. 2013). pWJ40 
was described in (Goldberg et al. 2014). pTarget (pWJ153) was described in 
(Goldberg et al. 2014); pTarget (pWJ267) was constructed by PCR using 
pWJ153 as a template and primers W1105/W1106.  
5.4 Plasmid DNA preparation 
     Plasmid DNA was purified from 2 to 6 ml of E. coli DH5α or S. aureus RN4220 
overnight cultures. For preparation from S. aureus cultures, cells were pelleted, 
re-suspended in 100 µl TSM buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.5 M 
sucrose) then treated with 5 µl lysostaphin (2 mg ml−1) at 37 °C for 1 h before 
treatment with plasmid miniprep reagents from Qiagen. Purification used Qiagen 
or EconoSpin columns.  
5.5 Conjugation 
     Conjugation was carried out by filter mating as described elsewhere (Morton 
et al. 1995). Briefly, donor (S. aureus RN4220 carrying pG0400 or pG0(mut)) and 
recipient cells were cultured overnight with appropriate antibiotics. The following 
day, equal amount (109 CFU) of donors and recipients were mixed in 5ml of fresh 
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BHI medium and vacuum-filtered through 0.45 mM filters (Millipore). Filters were 
incubated on BHI agar plates at 37 °C for 18 hours and grown bacteria were 
resuspended in 3 ml of fresh BHI. Serial dilutions were then plated on BHI agar 
containing the appropriate antibiotics for the enumeration of recipients and 
transconjugants. 
5.6 Preparation of electrocompetent S. aureus cells 
     S. aureus RN4220 or derivative strains were grown overnight in TSB medium, 
diluted 1:100 in fresh medium without antibiotics, then allowed to grow to an 
OD600 reading of 0.8–1.0. At this point, cells were pelleted at 4 °C, and two or 
three washes were performed using chilled, sterile dH2O. Cells were ultimately 
re-suspended in 1/100th (of the original culture) volume of chilled, sterile 10% 
glyercol and 50 µl aliquots were distributed for storage at -80 °C.  
5.7 Preparation of competent E.coli cells 
     Chemically competent and electrocompetent cells were made according to 
(Renzette 2011).  
5.8 E. coli λ-Red recombination 
     E.coli strain HME63 was used for all λ-Red recombination experiments. 
Recombineering cells were prepared and handled according to a previously 
published protocol (Sharan et al. 2009). Briefly, a 2 ml overnight culture (LB 
medium) inoculated from a single colony obtained from a plate was grown at 
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30 °C. The overnight culture was diluted 100-fold and grown at 30 °C with 
shaking (200 r.p.m.) until the OD600 was 0.4–0.5 (~3 h). For λ-Red induction, the 
culture was transferred to a 42 °C water bath to shake at 200 r.p.m. for 15 min. 
Immediately after induction, the culture was swirled in an ice-water slurry and 
chilled on ice for 5–10 min. Cells were then washed and aliquoted according to 
the protocol. For electro-transformation, 50 μl of cells were mixed with 1 nmol of 
salt-free oligos (IDT) or 100–150 ng of plasmid DNA (prepared by QIAprep Spin 
Miniprep Kit, Qiagen). Cells were electroporated using 1 mm Gene Pulser 
cuvette (Bio-rad) at 1.8 kV and were immediately re-suspended in 1 ml of room 
temperature LB medium. Cells were recovered at 30 °C for 1–2 h before being 
plated on LB agar with appropriate antibiotic resistance and incubated at 32 °C 
overnight. 
5.9 S. aureus transformation 
     Electrocompetent S. aureus RN4220 or derivative strains were thawed, mixed 
with appropriate amount (~100 ng) of dialysed plasmid DNA and incubated at 
room temperature for 5 min. Electroporation was performed using a GenePulser 
Xcell (BioRad) with the following parameters: 2900 V, 25 mF, 100V, 2mm. After 
electroporation, cells were immediately re-suspended in 200 µl – 1 ml of TSB and 
recovered at 37 °C for 2 h with shaking. Serial dilutions were then prepared 
before plating with appropriate antibiotics. Serial dilutions were then plated on 
tryptic soy agar containing appropriate antibiotics for transformants-counting.  
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     Transformation efficiency was expressed either as colony-forming unit 
(CFU)/µg of DNA or CFU/ml of recovered cells.  
5.10 S. pneumoniae transformation 
     Competent cells were prepared as described previously (Bikard et al. 2012). 
Briefly, an overnight THYE culture was diluted to OD600 of 0.05 in M1 medium 
(THYE with 0.2% BSA, 1 mM CaCl2, pH 7.1) and grown until OD600 of 0.15. Cells 
were pelleted and re-suspended in 1/10th (of the original volume) in M2 medium 
(THYE with 0.2% BSA, 1 mM CaCl2, 10% glycerol, pH 7.9), and frozen at −80°C 
for later use. For all genome editing transformations, cells were gently thawed on 
ice, and re-suspended in 10 volumes of M3 medium (THYE with 0.2% BSA, 
1 mM CaCl2, 100 ng/ml of competence-stimulating peptide CSP1 (Havarstein et 
al. 1995), pH 7.9). Editing constructs were added to cells at a final concentration 
of 0.7 ng/μl to 2.5 μg/μl, followed by incubation for 20 min at 37 °C before the 
addition of 2 μl of targeting constructs (similar concentration as the editing 
templates) and then incubated 40 min at 37 °C. Serial dilutions were then plated 
on agar containing appropriate antibiotics for transformants counting. 
5.11 Preparation of S. pneumoniae genomic DNA 
     For transformation purposes, S. pneumoniae genomic DNA was extracted 
using the Wizard Genomic DNA Purification Kit, following instructions provided 
by the manufacturer (Promega). For genotyping purposes, 700 μl of overnight S. 
pneumoniae cultures were pelleted, re-suspended in 60 μl of lysozyme solution 
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(2 mg/ml) and incubated 30 min at 37 °C. The genomic DNA was extracted using 
QIAprep Spin Miniprep Kit (Qiagen). 
5.12 Analysis of targeting requirement (PAM and seed sequences) by 
Cas9 complex in S. pneumoniae  
     The five nucleotides following the canonical spc1 target were randomized 
through amplification of R68232.5 genomic DNA with primers W377/L426. This 
PCR product was then assembled with the cat gene and the srtA upstream 
region that were amplified from the same template with primers L422/W376. 80 
ng of the assembled DNA was used to transform strains R6 and crR6. Samples 
for the randomized targets were prepared using the following primers: B280-
B290/L426 to randomize bases 1–10 of the target and B269-B278/L426 to 
randomize bases 10–20. Primers L422/B268 and L422/B279 were used to 
amplify the cat gene and srtA upstream region to be assembled with the first and 
last ten PCR products, respectively. The assembled constructs were pooled and 
30 ng was used to transform R6 and crR6. After transformation, cells were plated 
on chloramphenicol selection. For each sample more than 2 × 105 cells were 
pooled together in 1 ml of THYE and genomic DNA was extracted with the 
Promega Wizard kit. Primers B250/B251 were used to amplify the target region. 
PCR products were tagged and run on one Illumina MiSeq paired-end lane using 
300 cycles. 
166 
5.13 Generation of targeting constructs and editing templates for genome 
editing in S. pneumoniae 
     Targeting constructs used for genome editing were made by Gibson assembly 
(Gibson et al. 2009) of Left PCRs and Right PCRs (Table 2). Editing constructs 
were made by SOEing PCR (Horton et al. 1993) fusing PCR products A (PCR A), 
PCR products B (PCR B) and PCR products C (PCR C) when applicable (Table 
2). The CRISPR::Ø and CRISPR::ermAM(stop) targeting constructs were 
generated by PCR amplification of JEN62 and crR6 genomic DNA respectively, 
with oligos L409 and L481. 
5.14 β-galactosidase (Miller) assay 
     β-galactosidase (Miller) assays were performed as previously described 
(Zahner and Hakenbeck 2000).  
5.15 Fluorescence measurements for dCas9-mediated transcription 
repression and activation 
     Fluorescence was measured in a Tecan microplate reader. In all experiments, 
background fluorescence, or auto-fluorescence, was measured using a control 
strain lacking the GFP reporter. Auto-fluorescence was subtracted from the 
fluorescence readings and relative fluorescence was normalized to cells 
expressing a non-targeting crRNA (encoded by the BsaI sequences designed for 
spacer cloning). All transcription repression studies were performed in E.coli 
MG1655 cells.  
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     Transcription activation of the lacZ gene (encoding β-galactosidase) was 
studied in E. coli KS1ΔZ, a strain carrying the lacZ gene under the control of a 
weak promoter that can be induced by a cI-ω fusion (Dove and Hochschild 1998). 
KS1ΔZ also carried a deletion of rpoZ, the gene encoding the ω subunit of RNAP. 
Green fluorescence protein (GFP) assays were performed in an E. coli MG1655 
mutant, JEN202 (Bikard et al. 2013), in which rpoZ was replaced by a 
spectinomycin resistance gene.  
     All spacers used for dCas9-mediated transcription repression and activation 
are provided in Table 3.  
5.16 Northern blot analysis 
     RNA was extracted from overnight cultures using TRIzol (Invitrogen) following 
the manufacturer’s protocol. For each sample, 10 mg of RNA were separated on 
a 5% polyacrylamide gel. The RNA was electro-transferred to a charged 
membrane and hybridized either to a probe upstream (P511) or downstream 
(P510) of the T10 and B10 target sites. A probe annealing to the 5S rRNA (B507) 
was used as a control. 
5.17 Plasmid-curing assay 
     S. aureus RN4220 cells harboring both the wild-type CRISPR-Cas plasmid or 
its variant and the target plasmid (pWJ153 or pWJ267 contained the spc1 or 
gp43 targets, respectively) were cultured in TSB supplemented with 
chloramphenicol (10 µg/ml). ATc was added to a final concentration of 0.25 µg/ml 
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during log phase (at OD600 of 0.6-0.8). Plasmid DNA was prepared at designated 
time points, linearized with the common single cutter BamHI and subjected to 
agarose gel electrophoresis. 
5.18 Purification of Csm6 
     The pPS10, pPS42, pPS43 and pPS44 plasmids were transformed into E. coli 
BL21 (DE3) Rosetta 2 cells (Merck Millipore). Cultures (1 liter) were grown at 
37 °C in Terrific Broth medium (Fisher Scientific) containing 100 μg/ml ampicilin 
and 34 μg/ml chloramphenicol until the OD600 reached 0.6. The cultures were 
adjusted to 0.3 mM isopropyl-1-thio-β-d-galactopyranoside and incubation was 
continued for 16 h at 16 °C with constant shaking. The cells were harvested by 
centrifugation and the pellets stored at −80 °C. All subsequent steps were 
performed at 4 °C. Thawed bacteria were resuspended in 35 ml of buffer A (50 
mM Tris–HCl, pH 7.5, 500 mM NaCl, 200 mM Li2SO4, 20% sucrose, 15 mM 
Imidazole) containing one complete EDTA free protease inhibitor tablet (Roche). 
Triton X-100 and lysozyme were added to final concentrations of 0.1 % and 0.1 
mg/ml, respectively. After 1 hour, the lysate was sonicated to reduce viscosity. 
Insoluble material was removed by centrifugation for 1 hour at 15,000 rpm in a 
Beckman JA-3050 rotor. The soluble extract was mixed for 1 hour with 5 ml of 
Ni2+ -Nitrilotriacetic acid-agarose resin (Thermo) that had been pre-equilibrated 
with buffer A. The resin was recovered by centrifugation, then first washed with 
50 ml of buffer A, followed by washing with 50 ml of IMAC buffer (50 mM Tris-HCl 
pH 7.5, 250 mM NaCl, 10% glycerol) containing 50 mM imidazole. The resin was 
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subsequently resuspended in 10 ml of IMAC buffer containing 100 mM imidazole, 
and then poured into a column. The column was then eluted step-wise with 10 ml 
aliquots of IMAC buffer (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 10% glycerol) 
containing 200, and 500 mM imidazole. The 500 mM imidazole elutes containing 
the protein was pooled together and dialyzed against 50 mM Tris-HCl pH 7.5, 50 
mM NaCl, 10% glycerol. Subsequently Csm6 was purified using a 5 ml HiTrap Q 
Sepharose Fast Flow (GE Life Sciences), eluting with a linear gradient of 50 mM 
- 2 M NaCl. The peak fraction from the Q sepharose column was further purified 
by hydrophobic interaction chromatography using butyl sepharose 4 FF (GE 
Healthcare Life Sciences), eluting with stepwise lowering of ammonium sulphate 
concentration from 1 M to 50 mM. The final purification step was performed using 
size exclusion chromatography with Superdex 200 10/300 GL (GE Healthcare) 
column, using buffer B (50 mM Tris-HCl pH 7.5, 5% glycerol, 150 mM NaCl, 1 
mM TCEP). 
5.19 Csm6 RNA cleavage assay 
     RNA cleavage reactions were performed at 37°C with 1 µM of 5’-radiolabeled 
(R55 and R24) and 3’-radiolabeled ssRNA (R55) substrates and 10 µM of wild 
type or mutant Csm6. The reaction was carried out in reaction buffer containing 
50 mM Tris-HCl [pH7.5], 30 mM NaCl, 2 mM DTT and 1% glycerol. Reaction 
mixtures were withdrawn at specified time intervals and subsequently quenched 
with 90% formamide and 50 mM EDTA. Reaction products were separated by 
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denaturing PAGE and the gel was visualized by phosphorimaging. The 5’-
radiolabeled decade RNA ladder (Life Technologies) was used as a size marker. 
5.20 Csm6 DNA cleavage assay 
     DNA cleavage reactions were performed at 37°C for up to 2 hours with 1 µM 
of 5’-radiolabeled ssDNA (PS362) and dsDNA (PS362/PS363) substrates and 10 
µM of wild type Csm6. The reaction was carried out in reaction buffer containing 
50 mM Tris-HCl [pH7.5], 10 mM MgCl2, 30 mM NaCl, 2 mM DTT and 1% glycerol. 
Reaction mixtures were withdrawn at specified time intervals and subsequently 
quenched with 90% formamide and 50 mM EDTA. Reaction products were 
separated by denaturing PAGE and the gel was visualized by phosphorimaging. 
The 5’-radiolabeled 10 bp DNA ladder (Promega) was used as a size marker. 
5.21 Co-transcriptional DNA cleavage assay 
     Elongation complexes (ECs) were reconstituted essentially as described in 
(Samai et al. 2015). Typically, 2 μl 1 pmol/μl of template strand (TS) and 1 μl of 4 
pmol/μl RNA oligos were mixed in 1 × transcription buffer and incubated at 65°C 
for 5 min, followed by gradual cooling to room temperature. After addition of 1.5 
μl E. coli RNAP core enzyme (NEB), the reaction was incubated at 25°C for 25–
30 min and at 37°C for 1 min. Then, 4 μl 1.25 pmol/μl nontemplate strand (NTS) 
(pretreated by heating to 65°C for 5 min, then on ice for 2 min, and finally at 37°C 
for 2 min) was added and incubated for 10–15 min at 37°C. The final 
concentration of TS was 0.10 pmol/μl after adding supplement buffer to obtain 
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transcription conditions. Assembled ECs were kept on ice until use. In a 
transcription coupled DNA cleavage assay, 5 nM of EC was used and, Cas10- 
Csm complex was added to a final concentration of 5 nM and 50 nM. 
Transcription was initiated with the addition of 2.5 mM of RNTPs. All the 
reactions were performed at 37°C. For all the DNA cleavage time course 
experiments, RNTPs were added to the elongation complex (EC), prior to the 
addition of Cas10-Csm complex. After addition of Cas10-Csm, the samples were 
collected at 30 min, and quenched by mixing with Proteinase K (NEB) and 20 
mM EDTA. The DNA/RNA samples were then extracted using phenolchloroform-
isoamyl alcohol (25:24:1), ethanol precipitated and resuspended into loading 
buffer (90% formamide). The DNA products were heater at 95°C for 5 min before 
loading onto the gel. Cleavage products were resolved on a 12% denaturing 
polyacrylamide gels containing 7 M urea and visualized by phosphorimaging 
(Typhoon, GE Life Sciences). 
5.22 Phage infections and plate reader growth curves 
     S. aureus RN4220 cells were infected with phages ΦNM1γ6 or ΦNM4γ4 
during early log phase (at OD600 of 0.3-0.4). Plate reader growth curves were 
measured as previously described (Goldberg et al. 2014)  with slight 
modifications. Briefly, overnight cultures were launched from single colonies and 
diluted 1:250 in TSB broth supplemented with 5mM CaCl2 and appropriate 
antibiotics. After 1 h of growth, phage was added at a multiplicity of infection 
(MOI) of 5. Measurements were taken every 10 minutes. 
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5.23 Measurement of average burst size 
     S. aureus RN4220 cells with appropriate CRISPR-Cas plasmids were grown 
in TSB supplemented with 5mM CaCl2 and appropriate antibiotics to an OD600 of 
0.3-0.5. Cells were infected by ΦNM1γ6 at MOI = 0.1 for 5 min. Cells were 
immediately washed in TSB twice at 4 °C and re-suspended in equal initial 
volume. An aliquot of cells were spotted on heart infusion (BD) soft agar plates 
with a sensitive lawn (i.e. RN4220).  The rest of the cells were incubated at 37 °C 
for another 75 min before an aliquot of cells were spotted on a sensitive lawn. 
Agar plates were incubated at 37 °C for 16-20 hours before plaques were 
enumerated. Average burst size was calculated as the ratio of plaques formed at 
80 min to plaques formed at 5 min for each strain of interest. 
5.24 Extraction of total RNA in S. aureus 
     10-25 ml of S. aureus culture were pelleted and immediately frozen at -20 °C. 
Pellets were gently thawed at 4 °C and washed with 1 ml ice-cold TE pH 6.8. 
Pellets were re-suspended in 100 µl of ice-cold TE pH 6.8 and mixed with 750 µl 
of ice-cold TRIzol®. The mix was transferred into a 2 ml microtubes pre-filled with 
0.25 cm3 of 0.1 mm glass beads on ice. Cells were disrupted using 
MiniBeadbeater-1 (BioSpec Products) at an intensity setting of 42 for 30 seconds 
twice at 4 °C. 200 µl of chloroform was added to the disrupted mix was and the 
rest of RNA extraction protocol was followed according to TRIzol®. 
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5.25 Extraction of total DNA in S. aureus 
     10-25 ml of S. aureus culture were pelleted and immediately frozen at -20 °C. 
Pellets were gently thawed at 4 °C and washed with 1 ml ice-cold TE pH 8.0. 
Pellets were re-suspended in 400 µl of ice-cold TE pH 8.0 and mixed with 500 µl 
of ice-cold Phenol/Chloroform/Isoamyl alcohol (25:24:1) (Fisher Scientific). The 
mix was transferred into a 2 ml microtubes pre-filled with 0.25 cm3 of 0.1 mm 
glass beads on ice. Cells were disrupted using Mini-Beadbeater-1 (BioSpec 
Products) at an intensity setting of 42 for 30 seconds twice at 4 °C. The disrupted 
mix was centrifuged at 16,000 rcf for 10 minutes at room temperature. The 
aqueous phase was collected and mixed with 500 µl of chloroform and 
centrifuged as above. The aqueous phase was collected again and mixed with 1 
ml of isopropanol. Precipitated DNA was washed with 1 ml of 75% ethanol, air 
dried and dissolved in 50-300 µl of water. 
5.26 qPCR 
     S. aureus RN4220 were infected by ΦNM1γ6 (MOI=5) during early log phase 
(at OD600 of 0.3-0.4). qPCR was performed using Fast SYBR® Green Master Mix 
(Life technologies) and 7900HT Fast Real-Time PCR System (Applied 
Biosystems). For RNA samples, total RNA was treated with DNase I (Sigma-
Aldrich). 1 µg of DNase I treated RNA samples were subjected to reverse 
transcription using M-MuLV Reverse Transcriptase (NEB) and 100 ng of random 
hexamer (Invitrogen) according to the NEB protocol. The resulting cDNA was 
diluted 5 times as stocks. 500 nM of primers were used and 0.2 µl of the cDNA 
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stock was used as template for a 10 µl reaction according to the Fast SYBR® 
Green Master Mix protocol. For DNA samples, 25 ng of total DNA were used as 
template. The house-keeping rho gene was used as endogenous control for 
normalization (Theis et al. 2007). Primers used for amplification are shown in 
Table 5. 
5.27 RNA sequencing 
     Total RNA was treated with DNase I (Sigma-Aldrich) and subjected to TruSeq 
Stranded mRNA Library Prep Kit (Illumina) without rRNA depletion and Illumina 
NextSeq. Reads were aligned to reference genomes using Bowtie and sorted 
using Samtools. Using a custom script, sorted reads were accessed via Pysam, 
normalized as reads per million values, and plotted as the average over 
consecutive windows of 500 base pairs using matplotlib tools for IPython.  
5.28 Southern blot 
     20 µg of total DNA prepared from infected cells were digested with restriction 
enzymes EcoRI and PsiI for 5 hours and resolved on a 1% argarose gel. DNA 
fragments were transferred from the gel via capillary action to a Hybond 
membrane (GE Healthcare) using alkaline transfer (Sambrook 1989). Probes for 
the upstream and downstream fragments were produced via PCR of ΦNM1γ6 
DNA using primers W863/W864 and W865/W866, respectively, and α-32P-dATP 
in addition to regular dNTPs. Hybridization was performed at 65°C overnight in 
Church buffer (Sambrook 1989). 
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Table 1 Spacers used in Chapter 3 
Target 5-nt upstream Spacer sequence (5'-3') 5-nt downstream
gp5 TTTCG CCATTCATCTAATTTCAAGGCTATGTTTGATGTAG -
gp14 TTCTA CTACGTCCGTAATGCTAGGATTTGCAAATTTCTTA -
gp19 TTCTA CACCCATATCATCTAGTACAAGTAAATCAATATCA -
gp32 CAACT GTAAACCTTTGATTGCTCTTAGCTCGAGTTATGTGC -
gp43 TTCTA ATTCGTCATCTTCAAGTAATGCCTCTAAATCAATA -
gp43  (3 mm) TTCTA TTTCGTCTTCTTCATGTAATGCCTCTAAATCAATA -
gp43  (4 mm) TTCTA TTTCGTCTTCATCATGTAATGCCTCTAAATCAATA -
gp43 (5 mm) TTCTA TTTGGTCTTCATCATGTAATGCCTCTAAATCAATA -
gp43  (type II) - ACTTCACACAAGATAACATTATTGATTTAG AGGCA
gp50 TTCTA GTCCAATATTTTCTGCGATTTCATCTAGTGCTTCA -






















































































































































































































































































































































































































































































































































































































Table 2 Targeting constructs and editing templates used for genome 
editing in S. pneumonaie 
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Table 3 Spacers used for dCas9-mediated transcription repression and 
activation 























Z1 ACAACACGCACGGTGTTACATTAGGCACCC KS1ΔZ lacZ promoter
Z2 GATCTTCGACAACACGCACGGTGTTACATT KS1ΔZ lacZ promoter
Z3 GGCTGCAGGTCGGATCTTCGACAACACGCA KS1ΔZ lacZ promoter


























































































































































Table 5 DNA oligonucleotides used in Chapter 3 
Name Sequence (5'-3') Purpose
L342 aaaGGGCCCAAATAATATTTTCATTATAGCACCTC Cloning ofΔcsm6 
L343 aaaCGGCCGGAAAAAAATAAGGAATTTAAAGAGC Cloning ofΔcsm6 
PS11 CGCCATATGAAAATATTATTTAGTCCAATAGG Cloning of Csm6
PS12 CGCCTCGAGTAATAGCTCTTTAAATTCC Cloning of Csm6
PS243 GGTTTAAGAAATTCCATAGCCGCTAATTTAGATAC Cloning of Csm6 (R364A) 
PS244 GTATCTAAATTAGCGGCTATGGAATTTCTTAAACC Cloning of Csm6 (R364A) 
PS245 CGATATAAATGGTTTAGCAAATTCCATAGCCC Cloning of Csm6 (H3694A) 
PS246 GGGCTATGGAATTTGCTAAACCATTTATATCG Cloning of Csm6 (H3694A) 
PS247 GATATAAATGGTTTAGCAAATTCCATAGCCGCTAATTTAGATAC Cloning of Csm6(R364A, H369A)   
PS248 GTATCTAAATTAGCGGCTATGGAATTTGCTAAACCATTTATATC Cloning of Csm6(R364A, H369A)   
PS362 GTATAGGCACAGCGGGAATAAGGCTATCACTGATGTGCTCGAGTAACTTAACAGC DNA cleavage assay
PS363 GCTGTTAAGTTACTCGAGCACATCAGTGATAGCCTTATTCCCGCTGTGCCTATAC DNA cleavage assay
PS465 GAATCTAGTATGATTGGAGCAATTGcTTCTCCTGTAGTTAGAGATTTGCAAACC Cloning of Csm3(D32A)  
PS466 GGTTTGCAAATCTCTAACTACAGGAGAAgCAATTGCTCCAATCATACTAGATTC Cloning of Csm3(D32A)  
W614 GGTTATACTAAAAGTCGTTTGTTGG Cloning 
W852 CCAACAAACGACTTTTAGTATAACC Cloning 
W863 TATGTGGCCGAAAAAACCAAGC Probe for southern blot 
W864 TTGGATATCCATAGTTTTTACACC Probe for southern blot 
W865 ATGACATCAGAAGCGGTTGACG Probe for southern blot 
W866 TGGTTTAACAGTGCGTCTAATCC Probe for southern blot 
W893 TCCATTCGGTAAATCAATTGCAC gp43 qPCR
W894 TGTTTTTGAGATAAACGCATTTGC gp43 qPCR
W897 GAAGAATCAGATGGAGATAATGG gp42 qPCR
W898 AAGACGCTTGTTATATTCTTCTTG gp42 qPCR
W901 TGCAGTTAAACGCTACAACAGG gp44 qPCR
W902 CTTCATACTCCTTGAAATCGTTC gp44 qPCR
W905 TTATAGTAAGAAAACAGCAGAGTC gp37 qPCR
W906 AAACGCTCTTCTTGTATCTGTTC gp37 qPCR
W909 TGAATGCATTCAGCGGATCATC gp52 qPCR
W910 GATTGTCCAACTTGTTCAGACC gp52 qPCR
W915 GTCAATGACCATAACGCAGAAG rho qPCR as endogenous control
W916 CAATCGGTGTTACTAAATCCATG rho qPCR as endogenous control
W1085 GATTAGACATTCACCTTCAATAAC gp14 qPCR
W1086 TTGCGCTTGTCCTGTGATTTTC gp14 qPCR
W1105 CATCTTCAAGTAATGCCTCTAAATCAATAATGTTATCGATCTCCTAGGTCATTTGATATG Construction of pWJ267
W1106 GATTTAGAGGCATTACTTGAAGATGACGAATTAGAAGCATATTTATCAGAGCTCGTGCTA Construction of pWJ267
W1113 TATGAGATAATGCCGACTGTACTTTTTACAGTCGGTATCAGAGCTCGTGCTATAATT Cloning of pCsm6
W1127 GCTCTCTATCATTGATAGAGTGAGTTAAACAATGAGGTGCTATAA TG Cloning of pCsm6
W1128 GTAAAAAGTACAGTCGGCATTATCTCATATTTATCATAATAGCTCTTTAAATTCC Cloning of pCsm6
W1129 TCACTCTATCAATGATAGAGAGC Cloning of pCsm6
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